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Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of mature T-cell 
neoplasms with a poor prognosis. Recently, mutations in TET2 and other epigenetic 
modifiers as well as RHOA have been identified in these diseases, particularly in 
angioimmunoblastic T-cell lymphoma (AITL). CD28 is the major co-stimulatory receptor 
in T-cells which, upon binding ligand, induces sustained T-cell proliferation and cytokine 
production when combined with T-cell receptor stimulation, through many signaling 
molecules including VAV1. This thesis identifies recurrent mutations in CD28 in PTCLs, 
as well as mutations in VAV1. Two residues of CD28 – D124 and T195 – were 
recurrently mutated in 11.3% of cases of AITL and in one case of PTCL, not otherwise 
specified (PTCL-NOS). Surface plasmon resonance analysis of mutations at these 
residues with predicted differential partner interactions showed increased affinity for 
ligand CD86 (residue D124) and increased affinity for intracellular adaptor proteins 
GRB2 and GADS/GRAP2 (residue T195). Molecular modeling studies on each of these 
mutations suggested how these mutants result in increased affinities. We found 
increased transcription of the CD28-responsive genes CD226 and TNFA in cells 
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expressing the T195P mutant in response to CD3 and CD86 co-stimulation and 
increased downstream activation of NF-κB by both D124V and T195P mutants.  VAV1 
mutations affect many important domains and may also enhance co-stimulatory signal.  
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Epidemiology and clinical characteristics of peripheral T-cell 
lymphomas 
 
Peripheral T-cell lymphomas (PTCLs) are a large group of uncommon, 
heterogeneous diseases which comprise up to 20% of all non-Hodgkin lymphomas 
depending on geographic region.1,2  Most are derived from mature helper T-cells which 
express cluster of differentiation 4 (CD4), and besides anaplastic lymphoma kinase 
positive (ALK+) anaplastic large cell lymphoma (ALCL), most subtypes carry a dismal 
prognosis.1,2  In the Western world, the incidence of PTCLs has increased dramatically 
in recent years, amounting to 3.8% per annum in the United States,3 sharply augmenting 
both clinical and research interest.  A clinical diagnosis requires pathologic examination 
by expert hematopathologists, but because of their rarity and variable clinical 
presentations, these entities remain difficult to diagnose.  Since the publication of the 
WHO guidelines for the classification of lymphoid tumors and their later update,4,5 inter-
observer classification is fairly consistent depending on subtype.  How-ever, even with 
these guidelines, approximately 10% of cases initially diagnosed as a PTCL or related 
NK-cell lymphoma (NKCL) were misdiagnosed in the 2008 International Peripheral T-cell 
Lymphoma (I-PTCL) Group study1 which examined 1,314 cases of PTCL and NKCLs, 
the largest cohort ever examined for these diseases.  Such a margin of error highlights 
the necessity of expert review.  In general, the PTCLs have a poor overall survival, but 
depending on subtype (by pathologic review) and staging (by any or all of the Ann Arbor 
method,6 International Prognostic Index [IPI],7 or Prognostic Index for T-cell lymphoma 
[PIT]),8 prognosis can vary widely. Diagnosis and proper clinical evaluation of the 
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particular entity, therefore, is extremely important for prognostication and choice of 
therapy. 
The two most common PTCLs worldwide are PTCL, not otherwise specified (NOS; 
approximately 30%) and angioimmunoblastic T-cell lymphoma (AITL; approximately 
20%).1  In North America, PTCL, NOS accounts for 34.4% of all cases and AITL for 
16.0%.  Both of these diseases often present with focal or generalized lymph-
adenopathy, and constitutional B-symptoms (fatigue, fever, night sweats, and/or 
unintentional weight loss) are variably present (see Table 1).  Both of these entities 
primarily affect older individuals with a median age of 60 years for PTCL, NOS and 65 
years for AITL.  Although AITL has several unique histologic and immunophenotypic 
features, including a strong association with infection with Epstein-Barr virus (EBV), 
PTCL, NOS is a diagnosis of exclusion. 
In the I-PTCL study, 69% of PTCL, NOS patients presented at Ann Arbor stage III or 
IV, and 29% had greater than one extranodal site; for AITL, 89% presented at Stage III 
or IV, with 27% having more than one site of extranodal involvement.  Physical and 
blood exams were non-specific for both diseases, though hypergammaglobulinemia was 
more common in AITL than PTCL, NOS.  A summary of the findings can be found in 
Table 1. 
Given the geographical differences found in PTCL subtypes, it follows that different 
races and ethnicities may have differential predispositions to various PTCLs.  A recent 
survey of PTCL cases in America has found this to be the case;9 compared to whites, 
American Indians and Alaskan natives were 40% less likely to be diagnosed with PTCL, 
NOS, and too few were diagnosed with AITL to draw conclusions.  Conversely, blacks 
were 67% more likely to be diagnosed with PTCL, NOS, but 29% less likely to have AITL 
than whites.  Still, to contribute ethnicity as a major predetermining factor in PTCL likely 
ignores many broad, mostly unclear, factors. 
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This introductory section will serve to outline the current state of diagnosis and 
treatment of PTCL, NOS and AITL, to describe the current understanding of these 
diseases’ genetic and biological bases, and to discuss relevant background information 
on T-lymphocyte signaling pathways. 
 PTCL, NOS 
(N=340) 
AITL (N=243) 
Age, years   
Median 60 65 
Range 19-87 20-86 
 Number (% of total) as available 
Male 223 (65) 137 (56) 
Stage III-IV 232/334 (69) 214/241 (89) 
Extranodal sites >1 99 (29) 66 (27) 
Systemic (B) symptoms 118 (35) 168 (69) 
IPI > 1 72% 192/222 (79) 
PIT > 1 42% 154/233 (63) 
   
Clinical exam findings   
Skin involvement 16% 21% 
Hepatomegaly 17% 26% 
Splenomegaly 24% 35% 
   
Serum findings (not available for all 
cases) 
  
Elevated LDH 49% 146/223 (60) 
Elevated CRP 50% 84/127 (35) 
Hypercalcemia 5% 3/184 (1) 
Elevated β2-microglobulin 36% 53/92 (22) 
Hypergammaglobulinemia 29/201 (14) 74/166 (30) 
   
Survival   
5-year OS 32% 32% 
5-year PFS 20% 18% 
 
  





Pathologic characteristics of PTCL, NOS and AITL 
 
As stated previously, review by expert hematopathologists is crucial for diagnosis, 
and agreement on diagnosis is fairly consistent across experts.  Still, first-diagnosis 
inter-observer accord has been pegged at 75% for PTCL, NOS and 81% for AITL.1,3,10  
Clinical data in addition to pathologic data are important and informative for accurate 




Histologically, hematoxylin and eosin (H&E) staining will reveal various degrees of 
effacement of normal lymphoid architecture by small-to-medium sized lymphocytes (see 
Figure 1a).4,11  These lymphocytes may display nuclear atypia.  Usually, there is marked 
proliferation of high endothelial venules (HEVs), with clusters of atypical cells, often 
intermixed with plasma cells, eosinophils, and/or histiocytes.  Most cases display an 
increased follicular dendritic meshwork, and in some hyperplastic follicles are evident.  
Because the neoplastic cells partially mimic the normal function of their putative cell of 
origin, the follicular helper T-cell (TFH; see “Genetics/Cell of Origin), the B-cell 
compartment may be perturbed as well.  Frequently the B-cells are infected with EBV, 
Table 1.  Clinical characteristics of AITL and PTCL, NOS.  Clinical findings are 
usually non-specific, and clinical suspicion is usually low, contributing to the 
difficulty in diagnosis.  Both entities affect older individuals with a slight male 
preference, and the majority are diagnosed at late stage.  AITL tends to have a 
higher proportion of clinical exam findings, but serum findings between the two 
are inconclusive.  Both have a deplorable 5-year overall survival (OS) and 
progression-free survival (PFS).  Adapted and reprinted with permission. © 2008 
American Society of Clinical Oncology.
1
  All rights reserved.  Includes data from 





resulting in mild-to-moderate atypia and the appearance of a B-immunoblastic 
proliferation.  Rarely, Reed-Sternberg-like cells may be present, which may confound 
diagnosis.  There may also be an inflammatory infiltrate. 
On immunohistochemical staining, AITL cells express pan-T markers CD2, CD3 
(Figure 1b), and CD5, plus CD4.  A CD8 stain, however, may reveal large numbers of 
infiltrating cytotoxic T-cells, which may obscure diagnosis.  CD10, may be expressed in 
the neoplastic cells(Fig. 1d), as is the transcription factor responsible for TFH identity, 
BCL6.  Cells are usually negative for CD30, but any Reed-Sternberg-like cells may be 
positive for CD30 (Fig. 1e) or rarely CD15 (Fig. 1f).  Staining for TFH markers CXC 
chemokine ligand 13 (CXCL13) and programmed death-1 (PD1)12 will almost always be 
positive, and these two are particularly informative for the distinction between AITL and 
PTCL, NOS.  Stains for inducible co-stimulator (ICOS) will be generally high, though this 
is not thought to be particularly specific.13  Also, as AITL is characterized by the 
expansion of the follicular dendritic meshwork, markers of follicular dendritic cells (FDCs) 
– CD21 (Fig. 1c), CD23, CD35, and CNA42 – are often observed.  As AITL frequently 
occurs in the background of EBV infection, in situ hybridization (ISH) for Epstein-Barr 
virus-encoded small RNAs (EBER) highlights EBV-infected B-cells (Fig. 1f, inset); these 
EBER+ B-cells may be of various sizes, and may separately progress to, or be founders 






























Figure 1. Pathologic characteristics of angioimmunoblastic T-cell lymphoma with 
Hodgkin-Reed Sternberg-like cells positive for EBV. (a) Atypical large cells, 
some binucleate (arrow) are seen in a background of atypical lymphocytes. (b) 
Cytological atypia is evident in the T cells, highlighted with a CD3 stain. (c) 
Follicular dendritic cell meshworks are expanded, as seen with a stain for CD21. 
(d) CD10-positive atypical lymphocytes rosette large atypical cells with Hodgkin-
like features. The Hodgkin-like cells are positive for CD30 (e), CD15 (f), and 
EBER (inset).  Reprinted by permission from Macmillan Publishers Ltd: Modern 







The morphology of NOS ranges broadly but usually effaces normal nodal 
architecture (see Figure 2A,B).1,4,14  Cellular infiltrates may be monomorphous to highly 
polymorphous.  Nuclei are often irregular and hyperchromatic.  Large cells may have 
prominent nucleoli and mitoses.  Reed-Sternberg-like cells may be present, and HEVs 
are not prominent.  Because PTCL, NOS is a diagnosis of exclusion, there is no specific 
morphologic feature that points to its identification. 
Immunophenotypically, the neoplastic cells may express some or all mature T-cell 
antigens, or aberrantly lose some: CD5, CD7, and CD4 or CD8.  Some cases are CD30, 
CD56, CD20, CD79a, or CD52 positive; some are double positive for CD4 and CD8.   
Figure 2.  Pathologic characteristics of peripheral T-cell lymphoma, not otherwise specified.  (a) 
The tumor cells are variably-sized and consists of small cells with only minimal cytologic atypia 
and larger cells with irregular nuclear contours, prominent nucleoli, and brisk mitotic activity. 
Large cells with clear cytoplasm and Reed-Sternberg-like cells may be seen in some cases. 
Evidence of neoangiogenesis in the form of high endothelial venules is often seen. There is 
often a prominent component of reactive cells in the background, including small lymphocytes, 
eosinophils, macrophages, and plasma cells.  (b) Some cases of PTCL, NOS show Reed-
Sternberg-like cells. One such cell can be seen near the center of this image. The presence of a 
reactive infiltrate in the background consisting of eosinophils, lymphocytes, plasma cells, and 
histiocytes creates further resemblance to Hodgkin's lymphoma.  From Webpathology.com.
15
  




Some cases may have a substantial number of CD30+ tumor cells which raises the 
possibility of ALCL.  The T-cell receptor (TCR) β-chain is usually positive, which allows 
differentiation from γδ-PTCL subtypes.  Ki-67, a marker of proliferation, is usually fairly 
high.  Notably, it can be challenging to differentiate this entity from AITL due to the large 
variation in PTCL, NOS, so the markers which are on the neoplastic component of AITL 
– CD10, CXCL13, PD-1, ICOS, BCL6 – should be low to negative in PTCL, NOS.  
However, the follicular meshwork is variable, though low staining decreases the 
likelihood of AITL. 
Cytogenetic characteristics4 of both PTCL, NOS and AITL have been studied in very 
few cases, and these rare findings can be found in Table 2.  These changes are not 









PTCL, NOS AITL 
TCR clonality + + 
Chromosomal loss 4q, 5q, 6q, 9p, 10q, 12q, 13q 13q 
Chromosomal gain 7q, 8q, 17q, 22q 3, 5, 19, X; 22q, 11q13 
Table 2.  Cytogenetic characteristics of PTCL, NOS and AITL.  Although not 
frequent, these cytogenetic findings
4
 are sometimes identified in each entity. 
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Treatment and outcomes of PTCL, NOS and AITL 
 
There exists no standard of therapy for PTCL, NOS or AITL, but the anthracycline-
based regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), 
is usually used.  However, no treatment has been found that works consistently well.    
Thus, the major recommendation is to include patients on clinical trials, if possible.16  
This approach has led to the use of several new drugs, trials for most of which are still 
ongoing. 
Despite its prevalence, outcomes associated with the use of CHOP in PTCLs are 
poor.  The addition of etoposide (CHOEP or EPOCH)16  has been shown to improve 
event-free survival (EVS) but not overall survival (OS), particularly in younger patients 
(<60 years).  These formulations and dosages are based primarily on trials in aggressive 
B-cell non-Hodgkins lymphomas, and work fairly well in those diseases but much less 
well in PTCL, NOS.  Other, more intensive regimens have also been tried in the past, but 
uniformly these have shown no improvement in outcomes but increases in treatment 
toxicities.16,17  For AITL, retrospective analysis has found CHOEP to be superior to any 
other regimen.16 
Consolidation therapy remains somewhat controversial,16,17 but radiation therapy is 
used to some success for controlling localized disease.  However, because of the high 
relapse rate for PTCLs, current recommendations strongly suggest the 
chemotherapeutic regimen as a bridge to either autologous (preferred) or allogeneic 
hematopoietic stem cell transplant (HSCT or HCT).18-20  This is not true for lowest-risk 
tumors, which have a notably high OS after therapy with monitoring, but PTCLs only 
rarely present at low stage. 
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Auto-HCT, in which hematopoietic stem cells are collected from patients and then 
returned after marrow-ablative chemotherapy, works best for younger patients in their 
first clinical remission post-chemotherapy, though only a few large studies have been 
performed on which these statements have been based.  There have been more studies 
with smaller patient populations, using various induction and consolidation regimens and 
patients of various ages, stages and diagnoses; predictably, these studies have a wide 
range of outcomes, making it challenging to draw meaningful conclusions when taken 
together.  Understandably, relapse is not uncommon in autotransplant, but the outcomes 
are generally better than without transplant.  Allo-HCT is the only possible curative 
therapy in the case of relapsed or refractory disease.  Unfortunately, given the age and 
health of the majority of patients with PTCL, NOS and AITL, many are poor candidates 
for an allotransplant, leading to difficult clinical decisions.  Patients who are successfully 
engrafted may achieve clinical remission (CR), particularly in chemosensitive patients, 
and some may be cured.18-20  Graft-versus-host disease (GVHD), in which the 
transplanted immune cells attack recipient tissue, remains a major complication.17,18 
Patients who are poor candidates for transplant and/or who fail chemotherapy are 
generally given other chemotherapeutic regimens with variable but generally poor 
efficacy.  Patients may opt for palliative care, or for trials if applicable. 
Even in the past five years, many new drugs have become available which show 
promise in treating PTCLs. 
 Pralatexate, an antifolate, has been approved by the United States Food and 
Drug Administration (FDA) for PTCL when administered with leucovorin 
rescue to minimize side effects.21-23  This treatment has not been as effective 
in AITL as other PTCL subsets, including NOS.  Interestingly, there was no 
correlation between number of prior therapies and response to the drug,23 
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suggesting that the pathways targeted may be independent of the cancers’ 
clonal evolution in response to other chemotherapies. 
 Brentuximab vedotin, is an anti-CD30 antibody conjugated to monomethyl 
auristatin E, an anti-tubulin agent.  It is approved for use in CD30-positive 
PTCLs.24-26  In one study, effect was not directly correlated with tumor CD30 
expression, suggesting that drug activity is measurable even with low levels 
of CD30.  Unfortunately, its side effect profile is fairly serious, with many 
patients experiencing peripheral neuropathy which may not regress 
depending on length of brentuximab therapy, and a small percentage of 
patients developing progressive multifocal leukoencephalopathy.27 
 Histone deacetylase (HDAC) inhibitors, including romidepsin28,29 and 
belinostat30,31, are approved for use in patients who have failed at least one 
prior therapy.  Serious cardiotoxic side effects have been found in cutaneous 
T-cell lymphomas29 (CTCLs, a separate subset of PTCLs), so patients with 
moderate-to-severe cardiovascular disease (a large portion of the patient 
population) are ineligible. 
Further, there are currently 195 listed drug trials for PTCLs, many of which are 
attempting to perfect dosages of known drugs.  Some, however, aim to investigate the 
use of novel agents approved for other malignancies, including: 
 Mogamulizumab,32 an inhibitor of chemokine receptor CCR4 
 Tipifarnib,33 a farnesyltransferase inhibitor which prevents the activation of 
Ras-family GTPases 
 Selinexor,34 an inhibitor of nuclear exporter XPO1, which has been shown to 
maintain tumor suppressor activity in suppressor-mutated tumors 
 Alemtuzumab,35,36 an anti-CD52 antibody 
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 Lenalidomide,37,38 a strong immunomodulatory agent which works through 
many, mostly incompletely understood, mechanisms 
 Bendamustine,39,40 a nitrogen mustard with DNA-alkylating and anti-metabolic 
properties41  
 Bortezomib,42-44 carfilzomib,45 and ixazomib,46 second-generation proteosome 
inhibitors, have shown promise in CTCLs. 
 
With the use of CHOP or other anthracycline-based therapies for PTCL subtypes, 
overall survival for most subtypes is fairly low1 (Figure 3).  For both AITL and PTCL, 
NOS, 5-year overall survival is 32% with CHOP-like chemotherapy, and failure-free 
survival is 18% and 20%, respectively.  At one point, this figure was similar for most 
hematologic malignancies.  Since the use of rationally designed drugs like rituximab for 
B-cell lymphomas, including high-risk diffuse large B-cell lymphomas, these diseases 
have seen remarkable improvements in overall survival and progression-free 




Figure 3.  Overall survival of patients with the “common” 
peripheral T-cell lymphomas, by subtype.  AITL and PTCL, NOS 
both have 5-year survival rates of 32%.  Reprinted with 
permission
1
. © 2008 American Society of Clinical 
Oncology.  All rights reserved. 
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T-cell development and activation: an overview 
 
To explain specifically the development of peripheral T-cell lymphomas, it is first 
necessary to trace T-cell development.  This section briefly discusses T-lymphocyte 
generation in the post-natal human, and how T-lymphocytes become activated. 
 
From stem cell to mature αβ-T-cell 
 
Hematopoietic stem cells (HSCs) reside in the bone marrow and generate all blood 
cells through asymmetric cell division; when a long-term (LT) HSC divides, one daughter 
cell retains hematologic pluripotency whereas the other moves toward a committed 
lineage.  They are identified by surface expression of stem cell antigen 1 (Sca1) and c-
Kit without expression of any lineage-specific markers.49  In the case of cells that will 
become T-lymphocytes, a LT-HSC differentiates into a short-term HSC, which is further 
differentiated into a multipotent progenitor (MPP).  MPPs then divide to terminal, e.g. 
irreversible lineage commitment.  Classically, these progeny are either common 
lymphoid progenitors (CLPs) from which the entire lymphoid lineage is derived, or 
common myeloid progenitors (CMPs) from which the myeloid, megakaryocyte and 
erythroid lineages develop.  Recent work has suggested some trans-differentiation 
between CLPs and CMPs depending on the cytokine milieu, thymic environment, and 
bone marrow cellularity,50 but this complexity is beyond the scope of this chapter. 
To generate T-cells, CLPs, identified by the expression of IL-7Rα and low levels of c-
Kit and Sca1, emigrate from the bone marrow to the thymus.51  What causes this 
emigration is not fully elucidated, but adhesion molecules CD44 and lymphocyte 
function-associated antigen 1 (LFA-1) are both absolutely required.  Expression of B220 
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identifies a thymus-bound subset of CLPs known as CLP-2s which efficiently enter the 
thymus at its corticomedullary junction via CD44, LFA-1, and nearly a dozen other 
adhesion molecules.52,53  CLP-2s are believed to enter the thymus the same way that 
more mature lymphocytes enter peripheral organs: adhesion and tethering to ligand; 
rolling along the endothelia that line the capillary wall adjacent to the organ; and 
extravasation through the endothelial wall into the organ.54 
Mature T-cells can broadly be separated into two categories based on TCR chain 
expressed;55 the α-chain always pairs with β, which is termed an αβ T-cell.  T-cells 
expressing the αβ TCR are up to 98% of mature T-cells in humans.  The remaining 2% 
or so of T-cells express the γ and δ chains of the TCR which will not be further described 
here. The maturation process allows for the generation of appropriately functional β and 
α TCR chains, in that order. 
Pre-T-cells in the thymus go through three distinct phenotypic stages based on 
expression of CD4 and CD8, and the first stage is further divided into four substages.55  
The double-negative (DN) stages express neither CD4 nor CD8, and the cells migrate 
within the thymic outer cortex, but can be further subdivided based on surface 
expression of CD44 and CD25.  DN1 is CD44+CD25-; DN2, CD44+CD25+; DN3, CD44-
CD25+; and DN4, CD44-CD25-.  As the thymocyte progresses through the stages, it is 
sequentially attempting to make a functional T-cell receptor β-chain through 
recombination by action of recombination-activation gene 1 (RAG1) and RAG2, which is 
a hallmark of adaptive immunity in vertebrates.  At the DN3 stage, a pre-α chain (non-
recombined) is synthesized, to form a pre-TCR with the β-chain and components of 
CD3: γ, δ, and multiple ε and ζ chains. In the event that the β-chain is non-functional, the 
pre-T-cell will not be stimulated through its pre-TCR and therefore die. 
Once the DN4 stage is complete and there is a functional β-chain, the cells divide 
several times and then individually recombine the α-chain gene to encode a functional, 
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mature αβ-TCR; the pre-α chain is quickly lost.55  The cells also begin to upregulate 
CD8, followed by CD4, to begin the double-positive (DP) stage.  The cells migrate into 
the deep cortex of the thymus and interact with thymic cortical epithelial cells, which 
express major histocompatibility complex (MHC) classes I (which interacts with TCR and 
CD8) and II (which interacts with TCR and CD4) and present some self-peptides.  Thus, 
the DP cells are able to receive stimulation by MHC through their TCR, which sets up 
the next round of selection.  If the TCR is unable to interact with MHC, the T-cell 
undergoes apoptosis, termed “by neglect.”  But if the TCR interacts with MHC, usually 
weakly to moderately, it receives enough positive signal to stay alive, termed “positive 
selection.”  The nature of this positive signal transduction is discussed later in this 
section.  These selection steps theoretically ensure that T-cells which proceed to the 
next step in development are able to function. 
T-cells that pass positive selection then migrate to the thymic medulla to interact with 
medullary epithelial cells and dendritic cells, which are also coated with MHC presenting 
self-peptides.  At the end of this developmental stage, the T-cells will be single-positive 
(SP) and express only one of CD4 or CD8, which will limit their ability to interact to only 
MHC II or MHC I, respectively.  How these final maturation steps occur has only fairly 
recently been elucidated, and only after protracted experiments with conflicting data; the 
accepted model is called “instructional,” as opposed to a stochastic method of a random 
assortment of MHC interactions.55 
DP cells interacting with epithelial cells receive moderate signaling through MHC I / 
CD8 or MHC II / CD4.  When one signal is stronger, however, the T-cell first 
downregulates the receptor gene that received the primary signal,55 e.g. if signaling 
came through CD4, CD4 is mildly downregulated, so shortly after receiving signal, future 
CD4+ cells may appear CD4medCD8hi.  Eventually, CD8 will be methylated and 
downregulated, and CD4 transcription will be restored. 
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During the DP-SP transition as discussed above, the T-cells are still interacting 
heavily with epithelial cells in the medulla.  If the TCR reacts strongly with MHC, the T-
cell also undergoes apoptosis, termed “negative selection.”  This ensures that the 
nascent T-cells will not react strongly with peptides derived from the body’s own tissues, 
preventing autoimmunity.  The cells are still selected positively as well, such that cells 
that cannot maintain TCR signal throughout thymic migration will still undergo apoptosis. 
The particularities of the DN-DP transition, and to a slightly lesser degree DP-SP 
transition, are quite complex and are important for the understanding of T-cell 
leukemogenesis.56  T-cell leukemias are derived primarily from the various immature T-
cell subsets, so failures of negative selection, or oncogenic mutations which render cells 
unlikely to undergo apoptosis, are very important for leukemia biology.  T-cell 
lymphomas, however, are almost exclusively derived from mature T-cell subsets, which 
means this entire process of thymocyte maturation likely proceeded correctly and any 
directly lymphomagenic mutation occurred after maturation.  For one gene, this actually 
may not be the case (see “TET2” under “mutations” below). 
Once SP cells have completed their migration through thymic stroma, they are 
released into blood to circulate and migrate through secondary lymphoid tissue until an 
activation signal is found. 
 
CD4+ T-cell activation cascade 
 
Mature, naïve CD4+ T-cells circulate throughout the body and enter peripheral 
tissues by random or following chemokine attraction.  At any one time, the majority of T-
cells are likely within peripheral lymphoid organs – spleen, lymph nodes, and oral and 
gastrointestinal mucosa – in a quiescent state, expressing a mature TCR (αβ-complex 
and CD3γ, -δ, two -ε and two-ζ chains) interacting at random with antigen-presenting 
17 
 
cells (APCs) via MHC II.  When a T-cell finds an MHC presenting an antigen with which 
it can successfully interact above a certain threshold of affinity, it experiences signal 
transduction activation with pleiotropic effects, but as will be shown, sustained activation 
requires a second, co-stimulatory signal (see Figure 4).  To explain the pathways, first 
the canonical TCR activation cascade is described. 
Most of the early activation proteins are residents of the plasma membrane. Several 
are modified by fatty acid chains (palmitoyl and miristoyl groups) which anchor them in 
the membrane and prevent them from diffusing away, ensuring rapid transduction of 
signal on ligation.  Upon ligation of TCR/CD3 with a cognate antigen, the MHC II 
interaction with CD4 causes CD4 to recruit leukocyte C-terminal Src kinase (LCK).  In 
turn, LCK phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs) 
on the CD3ζ chains, which allows binding by Src kinase ζ-associated protein of 70 
kilodaltons (ZAP-70).  LCK then phosphorylates ZAP-70, which phosphorylates linker of 
activated T-cells (LAT).  LCK also separately interacts with and phosphorylates FYN, 
another Src tyrosine kinase.  LAT serves as the scaffold for binding a variety of signaling 
intermediates, including growth factor receptor-bound protein 2 (GRB2), and the VAV 
family, especially VAV1, both of which have many functional domains to interact with 
many different proteins. 
FYN, once activated, activates MEK and ERK through a variety of mechanisms, 
intermediate steps in the RAS-RAF-MEK-ERK classical cascade which phosphorylates 
dozens of other proteins as well as allows the nuclear translocation of transcription 
factors, including nuclear factor κ-B (NF-κB), Fos, Jun, MYC, and nuclear factor of 
activated T-cells (NFAT) among others.  FYN, along with LCK and ZAP-70, activates 
phosphatidylinositol 3-kinases (PI3K), which generate phosphatidylinositol triphosphate 
PIP3 and others, as well as activate protein kinase B (PKB/AKT), and phospholipase C 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































With the many different regions which may bind both membrane-bound and cytosolic 
proteins in the T-cell, GRB2 and VAV1 activate a plethora of other proteins, some of 
which will be cursorily mentioned here. Notably, GRB2 and VAV1 phosphorylate PLCG1, 
which in turn activates the calcium influx pathway via enzymatic cleavage of PIP3 into 
inositol triphosphate (IP3) and diacylglycerol (DAG).
57,58  DAG also activates FYN.58  
Activation of the calcium pathway also eventually phosphorylates NFAT which 
translocates to the nucleus and has widespread effects on transcription.  The guanine 
exchange factor (GEF) function of VAV1 in particular is important for activation of Ras-
superfamily kinases, including RHOA, which are together necessary for essentially all 
vital function of T-cell biology including actin polymerization, cell motility, global kinase 
pathway transduction, and global intracellular movement.59 
 
Costimulation in T-cell activation1 
 
As mentioned above, sustained T-cell activation requires two separate activation 
steps.  The first is through the variable CD3/TCR which is antigen-specific.  The other is 
through one of many invariant pathways.  CD3/TCR activation without co-stimulation 
induces anergy, in which the T-cell is not able to respond to even high-affinity stimulus or 
proliferate.60 
Classically, co-stimulation occurs through CD28, the prototypical costimulatory 
receptor and founding member of the B7 receptor family.  CD28 contains four exons: the 
first is a trafficking peptide which is cleaved off in final processing; the second contains 
the entire extracellular domain, which is how ligand interacts with CD28; the third is the 
transmembrane domain; and the fourth is the cytoplasmic domain.  Activated APCs (via 
cytokine secretion from innate immune cells, among others) increase the expression of 
                                                          
1
 Some parts rely heavily on Rohr et al. 2015 (ref. 122) 
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B7 family ligands,61 primarily CD80 (B7.1) and/or CD86 (B7.2).  Thus, when activated 
APCs bind naïve T-cells, T-cells ligate both CD3/TCR and CD28 (see Figure 4). 
The intracellular domain is necessary for signal transduction after ligand binding62 
and includes a YMNM motif, which, when phosphorylated, binds the SH2 domains of Src 
family kinases, PI3K regulatory subunits, and GADS/GRAP2 and GRB2. The CD28 
intracellular tail also contains two proline-rich motifs that bind the SH3 domains of 
various signaling proteins, including ITK, GRAP2, and LCK.63  The intermediates of 
CD28 activation further scaffold many of the interactions discussed under “T-cell 
activation.”  Together, CD28-mediated PI3K, GRB2, and VAV1 signaling increase NF-κB 
and NFAT nuclear translocation, augmenting T-cell survival, production of the 
proliferative cytokine IL-2, and cell cycling. 
Activation of both CD3 and CD28 underlies the exquisite complexity of adaptive 
immunity.  The various T-helper subtypes (see “Development and genetics” below) are 
only specified upon activation. 
Members of the B7 receptor family, not just flagship member CD28, have important, 
overlapping, and competing roles in T-cell signaling.  The prototypical competing 
member is cytotoxic T-lymphocyte antigen 4 (CTLA4) which, like CD28, forms 
heterodimers.64  CTLA4 shares high protein homology with CD28 but has some 
differences that result in major changes of affinity and function.64-68  First, CTLA4 also 
binds B7 ligands, but is able to do so at up to 100-fold greater affinity than CD28, both 
through greater affinity due to primary sequence differences but also because CTLA4 
homodimers can bind two B7 ligands whereas CD28, due to steric restraints, can bind 
only one.64  In binding ligand better than CD28, CTLA4 prevents the continued 
transduction of signal thorough CD28.  CTLA4 also initiates transendocytosis,69 in which 
it wrenches ligand out of the donating cell membrane and endocytoses the 
ligand/receptor complex for degradation, thereby forcibly preventing further CD28 
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activation.  The inhibition is not only limited to the extracellular interactions; the CTLA4 
intracellular domain is unable to bind important intermediates GRB2 and VAV1 and may 
directly activate or inhibit PI3K/AKT activation upon activation through poorly understood 
mechanisms.70,71  CTLA4 can also inhibit CD28 from interacting with intermediates 
including LCK and FYN.71,72  However, it is important to note that despite the 20 years 
that CTLA4 signaling has been studied, many articles directly contradict each other, 
such that most of these details still need to be fully verified.73 
Interestingly, the profoundly anti-stimulatory effects of CTLA4 are known to be 
exploited by many solid tumors;61 whereas neoantigens normally elicit an immune 
response, some cancers cause the activation of CTLA4, thereby inhibiting T-cell-
mediated immunity against the tumor.  Thus “releasing this break” via CTLA4-inhibitory 
antibodies has proven a powerful method to stimulate anti-cancer immunity. 
Another B7 receptor, programmed death 1 (PD1), also has an overall negative effect 
on T-cell activation and has similarly been exploited for anti-tumor immunity.  For 
PTCLs, PD-1 is of particular interest because it is important for identity and function of 
the T-follicular helper cell (TFH) as discussed in the next section.  Inducible co-stimulator 
(ICOS) and B- and T-lymphocyte attenuator (BTLA) are also B7 receptors similarly 







Development and genetics of AITL and PTCL, NOS 
 
In order to consider modes of investigation and treatment of these different PTCLs, it 
is important to understand as much as possible the cellular basis for oncogenesis.  
Thus, identifying the cell of origin (COO) is a necessary component of further inquiry.  
Only with the advent of next-generation sequencing (NGS) techniques has the 
technology existed to accurately examine small, otherwise unidentifiable subpopulations 
within a heterogeneous lymphoma.  Thus, the cell types of origin for various lymphomas, 
especially PTCLs, have only recently been described.  Gene expression profiling (GEP) 
has been an integral tool to understand COO and biology of PTCLs; the technique is 
explained under “Next generation sequencing” below. 
 
This section does not serve to review the entirety of our understanding of T-
lymphocyte subtype function, but only to highlight the differences between the putative 




From extensive GEP analysis of histologically identified AITL cases performed by our 
group74 and others75, the evidence supports the T-follicular helper (TFH) cell as the cell of 
origin for AITLs.  AITLs tend to have a high expression many genes associated with 
TCR signaling, including subunits of the TCR, CD3 genes, CD4, costimulatory CD28, 
other B7-family receptors CTLA4, BTLA, and PD-1, as well as many T-cell signaling 
intermediates.76  This supports the concept of strong TCR signals as required for TFH 
differentiation as discussed below, and that continued activation of this pathway would 
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be necessary for TFH-derived lymphoma to develop.  This does not imply that TCR 
activation is a unique feature of AITLs, however. 
TFH cells are resident T-cells of the germinal center (GC) which are necessary for the 
formation and maintenance of the GC reaction, a hallmark of adaptive immunity in 
vertebrates.  These cells are have surface expression of CD3 subunits and CD4, and 
are marked with expression of the master transcriptional regulator BCL6 and co-
expression of CXCR5, PD1, and ICOS;77-79 however, there is no universal agreement as 
to whether “true” TFH cells express all or some combination of these markers, nor is it 
certain whether cells that express all of these markers are necessarily TFH cells.  Thus, 
for clarity, another requirement – presence in the GC – ensures that T-cells that are 
likely involved in the GC reaction are known as TFH cells.  Cells outside the germinal 
center are termed “pre-TFH cells” depending on their expression of BCL6, CXCR5, PD1, 
and ICOS, but because they are not in the germinal center they cannot directly 
participate in the GC reaction. 
Although there is no consensus on the step-wise mechanism of TFH differentiation, 
there is strong experimental evidence that delineates a significant portion of the origin of 
the TFH cell.  First, antigen-experienced T-cells undergo priming.  Naïve T-cells express 
positive regulatory domain-containing protein 1 (PRDM1), whose product, known as both 
B-lymphocyte-induced maturation protein 1 (Blimp1) or PRDM1, is important for 
maintaining homeostasis in inactive T-cells80,81 and for preventing the TFH transcriptional 
program78 (see Figure 5 and Table 3). Upon T-cell receptor (TCR) / cluster of 
differentiation 3 (CD3) activation, a PRDM1+CD4+ T-cell can be exposed to a variety of 
cytokine microenvironments within peripheral lymphoid tissues.  Exposure to interleukins 
(IL)-21 and/or IL-6, both of which are elaborated by activated immune tissue but 
especially other T-cells,82 can induce the expression of BCL6 via their respective 
receptors IL-21R and IL-6R, which activate signal transducer and activator of 
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transcription 3 (STAT3).83  There is conflicting evidence as to the exact contributions of 
each of these cytokines to TFH identity, suggesting some or total functional redundancy; 
however, the loss of both significantly reduces TFH differentiation.
84  It is also possible 
that TFH cells are in fact first polarized towards the TH2 or TH1 lineages, then afterwards 
towards TFH; see “TH2” under “PTCL, NOS” below.  Either way, in these primed, newly 
BCL6-expressing CD4+ T-cells as in BCL6-expressing B-cells, mRNA does not 
necessarily lead to protein translation in B-cells,85,86 likely indicating an additional, as-of-
yet unidentified selection measure for determining TFH identity versus other TH subsets. 
 
Once translated, BCL6 in turn represses PRDM1 and master regulators of other TH 
subtype identity: TBX21, GATA3, RORγT, and FOXP3, which control TH1, TH2, TH17, 
and Treg transcriptional identities, respectively.78 BCL6 also leads to the upregulation of 
the chemokine receptor CXCR5, likely very early because BCL6 levels correlate well 
with CXCR5.82,88,89  CXCR5, with concomitant loss of chemokine receptor CCR7, allows 
these “pre-TFH” cells to home to follicles, where they can interact with antigen-presenting 
Figure 5. Simplified scheme of T-cell differentiation pathways and plasticity (dashed arrows). 
Secreted cytokines are listed in red.87  Reprinted with permission. 
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dendritic cells (DCs) as well as B-cells.90,91  Chemokine CXCL13 serves as the specific 
ligand for CXCR5 and is expressed primarily by professional antigen-presenting cells 
(APCs).  Expression of inducible co-stimulator (ICOS), a B7-family co-stimulatory 
molecule, by the BCL6+CXCR5+ T-cells is required to at the time of DC priming to set the 
stage for germinal center formation, and DCs express the ICOS ligand, ICOS-L.83,92  
Although a DC-dependent phase is necessary for robust TFH development, the T-DC 
interactions appear to be transient and must be replaced by T-B interactions for 
prolonged TFH function.
77,93  High-affinity TCR interactions with APCs, especially 
dendritic cells, generate more TFH cells as well.
94 
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Other transmembrane proteins appear to be involved in early TFH function but with a 
less clear mechanism.  Expression of CD28, the canonical T-cell co-stimulatory 
molecule and member of the B7 family, is necessary for the formation of TFH cells; 
CD28-null mice do not develop germinal centers,95,96 likely because they lack TFH cells.  
However, CD28 ligation has not been found to be necessary for TFH development at any 
Table 3.  Relevant T-helper subtype characteristic identities.  The 
prototypical inducing cytokines, signal-transducing intermediates, 
transcription factors, evolved cytokines, and primary cellular 
interactors are shown for the T-helper 1 (TH1), T-helper 2 (TH2), and 
T-follicular helper (TFH) cells. 
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specific stage.  Because of its primacy in early signal transduction through the TCR/CD3 
complex, it seems likely that CD28-null mice cannot have sufficiently high T-cell 
activation to generate TFH cells.  Similarly, OX40, a member of the tumor necrosis factor 
receptor family, is important for primed T-cell survival and can induce CXCR5 
expression,97 but OX40-null mice have near-normal GCs and normal TFH cell 
populations,98,99 suggesting a non-necessary role. 
Once TFH cells find their cognate B-cells, the germinal center takes shape.  BCL6 is 
even more upregulated in TFH cells during the GC reaction.
78  High levels of CXCL13 
expressed by FDCs as well as ICOS-L in FDCs and B-cells are required to maintain the 
follicular localization of T-cells, and a lack of ICOS on the T-cells or ICOS-L on B-cells 
prevents these T-B interactions.98  Robust ICOS stimulation leads TFH cells to upregulate 
production of IL-21, which positively signals to the neighboring B-cells, creating a 
positive feedback loop.76  This ICOS-mediated signaling can also be modulated 
downstream: mutations which decrease the activity of Roquin, an mRNA-binding protein 
which degrades ICOS mRNA, increase ICOS signaling and therefore TFH differentiation 
and function as well as increase GC size.100-102  TFH cells are the major control for GC B-
cell differentiation, through which B-cells undergo class switching and become long-term 
antibody-secreting plasma cells, via direct (OX40, CD40L) and indirect (IL-4, IL-21) 
mechanisms.76 
Other transmembrane proteins also take on important roles at the germinal center 
stage, notably of the B7 family.  In addition to CD28 and ICOS, PD1 is upregulated 
dramatically as T-B interactions increase in strength and both T and B compartments 
continue to expand clonally. PD-1/PD ligand 1 interactions between T and B cells are 
required for GC B-cell differentiation and activity as well as TFH activity.
103  T-cells co-
expressing PD-1 and CXCR5 are the prime representatives of active germinal center TFH 
cells.  Another B7 family member, B- and T-lymphocyte attenuator (BTLA), is 
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upregulated on TFH cells during the germinal center reaction and is probably involved in 
decreasing co-stimulation through overall negative regulation on CD28,104 although what 
exactly it does has not been completely assessed in relation to TFH cells specifically.  
The strongest ligand of BTLA, herpes virus entry mediator (HVEM), mediates a 
multifactorial inhibition105 of unclear significance in TFH function. 
It is important to note that despite the fairly detailed understanding of how TFH cells 
are generated, there exists no model which generates TFH in vitro that can retain their 
function.  By the same note, there is not an AITL model available that recapitulates the 
unique architecture of the disease or even is a phenotypic TFH cell.  This has 1) hindered 
research in TFH function, and 2) hindered research in AITL specifically. 
 
COO: PTCL, NOS 
 
GEP studies have also suggested that PTCL, NOS are also derived from T-helper 
subsets.74,106  Our group has shown that expression of the TH1-specific signature 
associated with TBX21 (historically known also as T-bet) or the TH2-specific signature 
associated with GATA3 transcription factors delineate distinct groupings of PTCLs by 
prognosis and active genes.  The canonical T-helper subset functions have been 
explored for the better part of 30 years, and as such it is much more convenient to 
consider the current understanding in review rather than by the multitude of original 
studies.76,87,107,108 
TH1 polarization is induced by exposure to interferon gamma (IFNγ) and IL-12, both 
of which are elaborated primarily by dendritic cells as well as natural killer (NK) cells.  
Signaling through IFNγ and IL-12 receptors activates STAT1 and STAT4, which induce 
the expression of TBX21.  TBX21 upregulates the production of IFNγ and tumor necrosis 
factor (TNF)α, leading to a Type I-polarized positive feedback loop through both 
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autocrine and paracrine mechanisms, as well as supporting its own transcription.  
TBX21 also suppresses GATA3, RORγT, FOXP3, and BCL6, thereby inhibiting 
polarization towards the other T-helper lineages.  The Type I response increases the 
proliferation and function of CD8+ cytotoxic T-cells, macrophages, and natural killer cells, 
among others, thereby preventing the spread of primarily intracellular pathogens, e.g. 
viruses, as well as bacterial infection.  IFNγ is also directly implicated in stimulating the 
release of immunoglobulin (Ig)G antibodies from B-cells, which increases macrophage 
function via pathogen opsonization. 
TH2 polarization, however, is induced by exposure to IL-4, which initially is released 
from other activated T-cells, eosinophils, basophils, mast cells, and dendritic cells.  The 
IL-4 receptor phosphorylates STAT6, which then upregulates IL4 as well as a number of 
other genes, including the master transcription factor of TH2 identity, GATA3.  With IL-4 
inducing a feed-forward loop, GATA3 suppresses the other T-helper transcription 
factors, further upregulates itself and IL4, and upregulates MAF (whose product, c-MAF, 
is another, but less lineage-specific, transcription factor).  Upon interaction with other 
Type II effector cells – the aforementioned basophils, eosinophils, and mast cells – TH2 
cells elaborate IL-5 and IL-13, migratory, maturational and proliferative signals for the 
Type II cells.  Also elaborated is IL-10, a potent suppressor of TH1 activity and a mild 
attenuator of all T-cell function. This response is associated with multicellular infections 
such as helminths, and is necessary for sustained B-cell stimulation, antibody 
production, and antibody class switching.  Because of the necessity of TH2 function for 
antibody-mediated immune function, the Type II response is of particular interest in 
autoimmune disease and allergy. 
Because of the TH2 activity on B-cells, it has been hypothesized that TFH cells may 
be derived from TH2 cells.
76  This is supported by the relative high levels of IL-4 within 
peripheral lymph organs, a result of resident dendritic cells as well as activated migratory 
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T-cells.  Further, TH2 cells are already primed to interact with B-cells whereas TH1 cells 
are not, also supporting the notion of a close relationship between the TFH and TH2 
phenotypes.  Therefore, activated T-cells in lymph organs may be first polarized towards 
TH2, and only with the addition of IL-21 and/or IL-6 stimulation at the appropriate time is 
BCL6 upregulated and the TFH program activated.  This could also partially explain why 
some BCL6+ cells do not become TFH cells; they are already TH2-polarized, and the 
exposure to TFH cytokines cannot overcome this effect, so BCL6 is thereafter 
downregulated.  However, others have found that although TFH cells may elaborate and 
respond to IL-4, the increase in IL-4 production is independent of the known TH2 
mechanism,89 suggesting TH2 independence.  At the same time, a recent study has 
found that murine activated T-cells in TH1-polarizing growth conditions in vitro express 
both Bcl6 and Tbx21 in an IL-12-dependent manner, and only after prolonged culture is 
the TH1 identity set and Bcl6 downregulated,
109,110 suggesting a TH1-TFH intermediate 
that only afterwards is specified; this was replicated in vivo by exposure to toxoplasma.  
Either way, it is likely that the “traditional” cytokine-mediated T-helper subtype 
specification in Table 3 and Figure 5 misses very important complexities. 
One other TH subset, the regulatory T cell (Treg), deserves special mention here 
because of its canonical function.  Identified by expression of the transcription factor 
FOXP3, Tregs profoundly suppress other T-cell function through expression of 
suppressive cytokines IL-10 and TGFβ, and through direct interaction.107,108  Tregs are 
present throughout the peripheral lymph system and are often found adjacent to active 
lymph tissue.  Thus, in order to develop into cancer, T-cells likely somehow escape the 
suppression caused by Treg cells.  This mechanism is unclear, but both AITL and PTCL, 
NOS have perturbed Treg compartments.  AITL cases tend to have fewer intranodal 
Tregs than normal tissues, and those cells that are there show a resting, e.g. inactive, 
phenotype.111 In fact, there is an example of a FOXP3-high PTCL, NOS which was 
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quickly fatal.112  Therefore, T-cell lymphoma cells must be altering other T-cell 
compartments, but how is not yet understood. 
Type I and Type II immune activation (mediated by TH1 and TH2 cells, respectively) 
have historically been discussed as mutually exclusive. The last fifteen years of work, 
however, has demonstrated not only many more transcriptionally and phenotypically 
distinct helper-T classes, including TFH cells as discussed above plus TH17, TH9, and 
TH22, which all interact to create the classically described types of activation.
87,107,108 
There is great plasticity between the different subsets, though TH1 and TH2 identities are 
thought to be relatively stable because they have built-in positive feedback loops to 
maintain the current polarization and inhibit all other helper lineages (see Figure 5).  This 
transcriptional flexibility has been found to be important for maintaining a variety of 
disease states and their animal models, suggesting that this plasticity may play further 
roles in T-cell lymphoma development that have not yet begun to be explored. 
 
Next-generation sequencing: new frontiers in PTCL research 
 
Only with the advent of next-generation sequencing (NGS) has the search for the 
genetic underpinnings of PTCLs begun to come to fruition.  There are three significant 
bottlenecks in obtaining meaningful sequencing data, and we will discuss each in 
relation to PTCLs. 
First chokepoint: the sample itself.  The greatest initial challenge in searching for 
genetic events in PTCLs has been the rarity of samples.  Pathologists and oncologists 
from multiple institutions working together to maximize sample collection, such as the 
members of the Leukemia/Lymphoma Molecular Profiling Project (LLMPP), has gone a 
long way to facilitating the sharing of samples and data. 
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Even then, collecting biopsies with enough residual tumor to get sufficient DNA has 
been problematic; as discussed in “Pathologic characteristics,” T-cell lymphoma cells 
tend to not grow in easy-to-separate clumps but be infiltrative, surrounded by normal and 
reactive tissues including normal T-cells.  Obtaining a 100% pure cancer sample, much 
less a 75% cancer sample, is therefore nigh on impossible, unlike in solid tumors or 
even some B-cell lymphomas which grow in sheets.4  In sequencing studies, these 
samples are considered to have low “tumor content.” Consider that it is relatively simple 
to obtain a high-purity population of neoplastic cells from solid tumors or different types 
of leukemia, either by excising part of the tumor or by collecting circulating neoplastic 
cells from blood.  For these, a relatively high proportion of the assayed nucleic acids will 
come from the neoplasms; one refers to these samples as having high tumor content.  In 
the case of almost every PTCL subtype, neoplastic cells and normal cells exist side-by-
side in affected organs, and it is difficult to effectively distinguish them by histology.  
Excised tissues, therefore, may have extremely varied, but often quite low, neoplastic 
contributions. Further, PTCLs generally do not have a leukemic phase in which large 
numbers of neoplastic cells are released into the blood,4 so harvesting peripheral blood 
mononuclear cells (PBMCs) has even a lower likelihood of collecting neoplastic cells for 
analysis. 
Tissue processing is the next complication.  Biopsies for routine pathologic practice 
are formalin-fixed and paraffin-embedded (FFPE) before sectioning and staining; the 
fixation process leads to severe DNA fragmentation and damage and therefore 
sequencing artifacts, mostly C>T|G>A, thought to be due to cytosine deamination during 
formaldehyde removal.113  Storing biopsies “fresh frozen,” by flash freezing and 
embedding in a polyethylene glycol / polyvinyl alcohol-based medium (OCT; “optimal 
cutting temperature”), prevents this potential problem.  However, this method is more 
labor-intensive, more expensive, less useful in standard pathology lab practice, and 
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requires long-term storage at -80 degrees Celsius or in liquid nitrogen, all of which put 
this method beyond what most lab practitioners and institutions are willing and able to do 
on a regular basis.  In the past five years, technological developments including 
commercially available, kit-based techniques have been optimized for the extraction of 
FFPE DNA or RNA, significantly decreasing artifactual reads and increasing overall 
quality of sequencing output.114  This not only increases the use of new cases, but also 
opens up archival tissue to sequencing examination.  Other storage-related problems 
can arise, e.g. if the sample has become too oxidized, DNA quality may be too low to 
use,114 but many archival tissues will still be able to be extracted for sequencing. 
It is important to note that PTCLs as opposed to other cancers have additional issues 
raised during sequencing.  When performing sequencing studies, usually a normal, non-
cancerous tissue from the same patient is sequenced as a control to determine whether 
any variants found are germline, e.g. not cancer-specific, or somatic, mutations in the 
cancer.  For historic PTCL cases, no normal was ever taken, and even in the 
sequencing era cases often do not have corresponding normal tissues.  Thus, it is 
harder to call a variant somatic without something to which it can directly compare.  
Prospectively, normal tissue, in the form of swab of unaffected skin or nucleic acid 
extracted from peripheral blood, can be collected, but it is difficult to ensure that 
standard collection practices are followed when the samples come from all over the 
world.  In this study, no cases have corresponding normal tissues to which mutant calls 
can be compared, but variant frequency can serve as a partial surrogate; if the variant 
frequencies (VF; described below) approximate 50% or 100%, the variant is likely to be 
in all of a single or both alleles, and is possibly germline.  However, for most of these 
cases, VF is much less than 50%, indicating a heterogeneous population, some of which 
contain a mutant allele; the most likely cause is if the mutation is somatic. 
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Having obtained tumor samples of high quality, either DNA or RNA (or both), the 
next bottleneck has been in the actual sequencing techniques.  Consider the time and 
cost of sequencing an entire human genome in 2000, when the first genome was 
completed: 10 years, nearly $100,000,000.  This cost was from using Sanger 
sequencing, and from paying all the man-hours to sequence and analyze.115  The 
Sanger method uses serial addition of dideoxynucleic acids which can be incorporated 
into a growing DNA strand but cannot serve as a substrate for elongation.116  Four 
reactions were performed, one for each of the dNTPs, resulting in four tubes each with a 
multitude of chains of different lengths.  The chain-terminated sequences were 
sequentially loaded into a polyacrylamide-urea gel and separated by electrophoresis.  
Thus, a user could quickly read through short segments when developed, e.g. by 
radiography.  This method is for the most part accurate, but has several problems, 
including that it only sequences any given base one time, it is problematic in repetitive 
sequences, resolution of single bases may be difficult depending on the imaging 
platform, and it is incredibly labor-intensive.  Capillary-based Sanger sequencing 
machines allowed unattended sequencing while ensuring multiple rounds of coverage 
over the same bases, increasing accuracy dramatically and bringing the maximum 
number of bases sequenced per day up to approximately 115 kilobase pairs (kbp; 
115,000 base pairs), which is what was in use by the end of the completion of the 
Human Genome Project.   
To combat the problems that Sanger sequencing could not overcome, as well as 
increase the throughput of sequencing studies, massively parallel sequencing (MPS) / 
next-generation sequencing (NGS) techniques were developed in the first decade of the 
21st century.  Several commercially available machines exist but they all have many 
similarities.115,117  This study uses whole-transcriptome sequencing (WTS)/RNASeq and 
targeted sequencing, so these two modalities will be discussed here.  Simultaneous 
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reading allows for much greater depth, or number of times a given base is read, 
decreasing error.  It also allows for a greater number of base pairs to be read with no 
bias – the Illumina HiSeq X10 can read up to 1.8x106 kbp,118 an approximate 15 million-
fold increase over what was in use in the year 2000.  Sequencers also include a quality 
value for every base, which is the sequencer’s estimate in confidence of the read given 
the values of the other bases not called. 
For most WTS analyses117 including the one used here, “library preparation” occurs 
first, in which polyadenylated mRNAs are isolated and converted to complementary DNA 
(cDNA), and broken into small fragments with an approximate median of 50-150bp.  
During library preparation, adaptors are ligated, and cDNA with adaptors are selected.  
An additional “barcode” may be ligated between the adaptor sequences and the target to 
run multiple sequences together.  Adaptor-ligated fragments are then bound in solid 
state, e.g. to a plate or flow cell, and the cDNA may be amplified by a high-fidelity 
polymerase.  Finally, the fragments are sequenced, though by what mechanism is 
dependent upon the machine. 
The WTS in this study was performed on an Illumina GIIx machine, which uses the 
standard Illumina library preparation as described in the preceding paragraph.  The 
amplification step, called “bridge amplification,” ensures that there is enough substrate to 
allow the optical system to “see” each base when added and relies on segments 
complementary to the adaptors already adhered to the flow cell.  This innovation allows 
less input (as low theoretically as a few nanograms) of sample, and increases the 
likelihood of accurately identifying rare sequences, but also introduces potential false 
reads due to polymerase error.  The bridge amplification process creates “clusters” of 
identical sequences physically close together on the flow cell.  The clusters are then 
repeatedly run and detected by the machine, completely eliminating humans from the 
actual sequencing steps.  When run, the flow cell is flooded with fluorescently labeled 
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DNA bases which have a blocking group on the 3’ end of the base, preventing additional 
incorporation of other bases.  Once bound, the clusters are read by the fluorescent tag 
on the newly-incorporated base.  The tag is then cleaved, and the blocking group is 
chemically substituted with a hydroxyl group, allowing each strand to incorporate a new 
base on the next run.  
We also perform targeted exome sequencing,119-121 which employs a different 
capture technique than WTS.  For this study, cDNA was PCR-amplified by multiple 
primers targeting each exon, and the amplicons were sequenced as described above.  
This method allows incredible depth of the targets of interest, but can introduce PCR 
errors which are then amplified during processing. 
The ability to generate all these sequences has been a boon to PTCL research (and 
all genetics), but it has also generated problems with copious volumes of data.  Raw 
sequencing files vary wildly in size due to the type of sequencing performed, the amount 
of primary sample input, and the depth of sequencing.  Quality data are also included 
within the file and can double or triple the file size.  And one does not usually sequence 
a single case by itself when looking for cancer-causing changes; dozens to hundreds of 
cases are included in a single run.  For many, sheer storage can become a problem.  
Further problematic is the amount of space required to analyze data as described below.  
Processing can tie up even good computers for extended periods of time, which is 
decreased by the use of cloud computing so that many of the calculations can be done 
on a separate server. 
Sequencing data must go through several steps before meaningful results are 
available, and each step of processing can employ one or more of dozens of available 
algorithms, which may lead to discrepancies even when different groups use identical 
sequencing data.  For PTCLs, our group has developed its own analysis 
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pipeline,74,106,122-124 which specifically is used for our high- and low tumor-content 
samples. 
First, low-quality reads are eliminated from further processing to decrease strain and 
time.  Then, the raw reads must be aligned to the reference sequence: for humans, the 
most recent public version of the Human Genome Project is usually used.  Once aligned, 
differences from references are then called; in cancer, these are putative mutation sites.  
However, it is important to note that single nucleotide polymorphisms (SNPs), which are 
classified as differences from reference in 1% of the population or greater, will be found 
in mutation calling because they differ from reference.  Considering their high frequency, 
most sequencing studies looking for novel mutations, including the present work, filter 
out SNPs at this stage using the dbSNP database maintained as part of the Human 
Genome Project. 
Once mutations are called, further analysis can be performed to help decide whether 
the putative mutations have significant effect on the product.  That is, for proteins, the 
putative substitution can be assessed automatically for likelihood to be functional, 
deleterious, or neutral.  For non-coding RNAs assessed through cDNA, mutations which 
affect seed site or other binding site can potentially be assessed, though the tools to do 
this well are still in development. 
Finally, though, the end user has to decide whether a mutation is likely relevant by 
themselves, and to verify some of the mutations by separately performing PCR and 
Sanger sequencing. 
One major use of RNASeq that is not for mutational analysis is gene expression 
profiling (GEP)74,106,117 when cDNA is used as the input.  GEP can be performed by 
array, wherein unique probes are bound to individual microwells of a chip, cDNA is 
loaded onto the whole chip, and the probes hybridize to their specific complementary 
cDNA segments during processing.  The binding is read by degree of fluorescent or 
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chemiluminescent output, and therefore is a semi-quantitative measure of each 
individual target.  NGS can do the same thing in silico: numbers of reads of any 
transcript can be found and therefore compared proportionally to other samples.  Unlike 
an array-based GEP, sequencing does not rely on pre-made probes, making RNASeq 
able to find any transcript, not just what is pre-loaded into the array.  However, 
amplification procedures can artificially alter the ultimate expression levels due to bias in 
the amplification or sequencing process. 
 
Known mutations in PTCL, NOS and AITL 
 
The first discovered set of mutations, and among the most frequent in PTCLs, affect 
genes which alter epigenetic stability. These are primarily loss-of-function mutations in 
TET2 and DNMT3A, and a gain-of function mutation of IDH2. 
Ten-eleven translocase 2 (a.k.a. Tet methylcytosine dioxygenase 2; TET2) has at 
least one loss-of-function (LOF) mutation in approximately 80% of PTCL cases122,123,125-
129 and catalyzes the conversion of 5-methycytosine (5mC) to 5-hydroxymethylcytosine 
(5hmC), the first step in cytosine demethylation.  In promoter regions, methylated 
cytosines in CpG islands (CG dinucleotides) repress transcription; TET2 catalyzes, 
therefore, the first and rate-limiting step in preventing an abnormal global accumulation 
of 5mC.  Mutations found in PTCLs usually lead to a loss of TET2 function, either by 
premature translational arrest and nonsense-mediated decay or loss of catalytic activity. 
Either event is expected to prevent demethylation and thus effect global 
hypermethylation.  This has indeed been found to be true in TET2-mutated murine 
leukemia models130 as well as in primary TET-mutated glioblastoma131 and acute 
myeloid leukemias (AML).132  Unfortunately, it has been difficult to assess the 
contributions of TET2 mutation in PTCL for several reasons.  First, as described above, 
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the incidence of PTCLs is overall much lower than that of either glioblastoma or AML, 
leading to a lack of primary tissues.  Even more importantly, PTCLs often have much 
lower tumor content than samples of the other cancers, likely masking less striking 
specific epigenetic changes.  TET2 mutations are particularly interesting because 
homologs with the same function, TET1 and TET3, are also mutated in myeloid 
leukemias133 and gliomas131 and often mutually exclusively from TET2, but never in 
PTCLs.  Why exactly this is the case is unclear. 
One additional layer of complexity with TET2 is that it is mutated fairly frequently in 
the general population without hematologic malignancy as well, with approximately 
2.0%-3.5% carrying at least one hematologic malignancy-related somatic mutation 
including TET2.134,135  This suggests that TET2 mutations may serve as the founding 
changes for a wide variety of malignancies.  In reference to lymphopoiesis, it suggests 
that the thymocytes may already have TET2 mutations; therefore, even PTCLs may 
have predisposing mutations before maturation. 
DNA methyltransferase 3A (DNMT3A) is mutated in about 30-40% of PTCL, NOS 
and AITL, but usually only in cases that have TET2 mutations as well.123,129,136  It 
catalyzes de novo CpG methylation, thereby decreasing transcription of affected genes.  
Its mutations almost exclusively occur in the methyltransferase domain and lead to a 
loss of methyltransferase function.137  Thus, its mutations would be expected to lead to 
global hypomethylation, or at least hypomethylation of genes that should be silenced.  
DNMT3B, a family member with unique functions, is not found to be mutated in PTCLs, 
nor is it mutated in other malignancies either. 
Isocitrate dehydrogenase 2 (IDH2) is found to be mutated in approximately 30% of 
AITLs and only rarely in PTCL, NOS.123,138  It is an enzyme of the Krebs cycle which 
converts isocitrate to α-ketoglutarate (α-KG).  Unlike the other enzymes above, IDH2 is 
mitochondrial.  Also unlike the other enzymes, IDH2 mutations occur at a single codon, 
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arginine 172, mutated usually to either serine or lysine, and these mutations are gain-of-
function (GOF), rather than LOF.  Mutant IDH2 gains additional catalytic activity, 
converting isocitrate to 2-hydroxyglutarate (2-HG) in addition to α-KG.  2-HG cannot be 
used in subsequent steps of the Krebs cycle, so it diffuses out of the mitochondria and 
into the nucleus, where it directly interferes with 5mC-5hmC conversion by TET2 by 
competing with α-KG, a cosubstrate in the enzymatic reaction.  It similarly inhibits 
several other dioxygenases, including a number of lysine demethylases.139,140 
Interestingly, IDH2 mutations in AITL occur almost exclusively in the background of 
TET2 mutations, whereas in AML132 and gliomas,141 IDH2 mutations are mutually 
exclusive from TET2 mutations.  Similarly, both AML and glioma may have IDH1 or IDH2 
mutations, and they are mutually exclusive, whereas in AITL, only IDH2 is mutated.  
Further, leukemias and gliomas have two hotspots for IDH2 mutations – R140 and R172 
– whereas PTCLs only appear to have the latter.  Our group has recently attempted to 
delve into the specific mechanisms of IDH2 mutation on T-cell function and found 
epigenetic alterations on several T-cell-specific genes123 that may contribute to the 
pathogenesis of AITL. 
The most unexpected recent addition to the PTCL mutation spectrum is in RHOA, 
the flagship member of the RHO GTPase superfamily.  Approximately 53-70% of AITL 
cases and 20% of PTCL cases have identical mutations at glycine 17, mutated to valine 
or less frequently glutamate.123,125,127,128  These mutations appear to occur exclusively in 
the background of TET2 mutation.  RHOA and its close family members are central to a 
host of cellular processes, including signal transduction, cellular migration, calcium 
homeostasis, and mitosis, among others.  The G17V mutation has been studied in vitro 
and in non-T cells.125,127,128  The substitution of glycine 17 prevents the G-box, the 
domain responsible for stabilizing guanine nucleotide, from binding guanine.  Therefore, 
RHOA G17V cannot bind GTP or GDP and therefore cannot perform any of its effector 
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functions.  Further, through mechanisms not entirely clear (though there are some 
hypotheses: see “Discussion”), the RHOA mutant prevents WT RHOA from its effector 
functions, including binding of GTP and formation of stress fibers.  RHOA G17V mildly 
augmented Jurkat T-cell proliferation as well. 
Considering the importance of the TCR pathway to PTCL maintenance from the 
GEPs, it follows that mutation of members of this pathway which could be relevant to 
lymphomagenesis and cancer progression.  Interestingly, few mutations have been 
reported.  One study shows a few mutations in FYN,125 which have not been reported 
since; another shows a mutation in VAV1, and a few in CD28;128,142 and yet a third study 
finds single case of a fusion between ITK and SYK,143 two kinases important in early 
TCR transduction (see “CD4+ T-cell activation cascade”).  However, none are well-
characterized.  Other studies have also found high expression platelet-derived growth 
factor receptor α (PDGRFA) without mutation,144 and relatively frequent mutation of 
phospholipase C γ-1 (PLCG1),145,146 both of which can increase TCR/CD3 activation 
responsiveness, though these findings have not yet been replicated in any other patient 
population or sequencing dataset. 
 
With this understanding of the current state of research in peripheral cell 
lymphomagenesis, this thesis delves into mutation and activation of the CD28 co-







CHAPTER 1: MATERIALS AND METHODS 
Patient specimens 
 
The clinical and pathological characteristics of the patients included in the study have 
been published106,122,123 and are included in Table 4 below. We included 20 molecularly 
diagnosed AITL lymphomas for transcriptome sequencing in our study and 85 additional 
cases of molecularly and/or histologically diagnosed AITL, PTCL-NOS, and ALK-
negative ALCL. This study was approved by the Institutional Review Boards of the 
University of Nebraska Medical Center and City of Hope National Medical Center. 
Case Disease Sex Age Time Status CD28.call CD28mut TET2 RHOA 
001 AITL Female  76.51 2.90 1 0   0 1 
002 AITL Male  76.68 4.66 0 0   1 1 
003 PTCL Female  66.52 5.81 1 0   0 0 
004 PTCL Male  49.73 0.46 1 0   1 1 
005 PTCL Male  97.36 0.04 1 0   0 0 
006 PTCL Male  64.55 0.04 1 0   0 0 
007 PTCL Female  70.28 3.12 1 0   1 1 
008 PTCL Male  68.67 1.46 1 0   0 0 
009 ALCL.neg Male  64.11 0.84 1 0   0 0 
010 AITL Male  58.03 0.66 1 1 T195P 1 1 
011 PTCL Female  75.26 8.70 0 0   0 0 
012 PTCL Female  78.89 1.33 1 0   0 0 
013 PTCL Male  66.25 4.28 0 0   0 0 
014 PTCL Male  80.92 0.59 1 0   1 0 
015 AITL Male  40.34 14.96 0 0   0 0 
016 AITL Male  40.46 3.85 0 0   1 1 
017 PTCL Female  74.52 0.09 1 0   0 0 
018 AITL Female  74.76 6.92 0 0   1 1 
019 AITL Male  66.63 2.21 0 1 D124E 1 1 
020 AITL Female  65.99 1.17 0 0   0 0 
021 AITL Female  64.39 1.02 0 0   1 1 
022 PTCL Female  54.67 2.88 0 0   1 1 
023 AITL Male  65.49     0   1 1 
024 AITL Male  68.07 6.34 0 0   1 0 
025 AITL Male  63.00     0   1 0 
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026 PTCL Male  19.37     0   0 0 
027 AITL Female  52.19 3.83 0 0   1 0 
028 AITL Female  74.54     0   1 0 
029 AITL Male  45.44     0   1 0 
030 PTCL Female  72.14 4.31 0 0   1 0 
031 AITL Female  73.58 0.07 1 0   1 0 
032 AITL Female  69.31 0.20 0 0   1 0 
033 AITL Male  33.30     0   1 0 
034 AITL Male  59.22     0   0 0 
035 PTCL Male  33.77     0   1 1 
036 AITL Female  79.95 0.01 0 0   1 0 
037 AITL Male  63.43 0.44 1 0   1 1 
038 AITL Male  52.90     0   1 0 
039 AITL Male  66.95     0   0 1 
040 PTCL Female  68.70     0   1 1 
041 AITL Male  60.84 0.74 0 0   1 1 
042 AITL Female  67.93     0   1 0 
043 AITL Female  47.50 0.52 0 0   1 1 
044 PTCL Male  65.23     0   0 0 
045 PTCL Male  65.23     0   0 0 
046 PTCL Male  27.92     0   0 0 
047 AITL Male  69.33 2.25 1 0   1 1 
048 PTCL Female  73.52 7.92 1 0   1 1 
049 AITL Male  68.07 0.32 1 1 T195P 1 1 
050 AITL Female  57.83 0.77 1 0   1 1 
051 AITL Male  44.10 3.06 0 0   1 1 
052 AITL Female  58.86 0.25 1 0   1 1 
053 PTCL Male  51.05 0.92 1 0   0 0 
054 PTCL Male  76.02 1.26 1 0   1 1 
055 PTCL Male  69.52 2.30 1 0   1 1 
056 PTCL Male  63.72 4.52 1 0   1 0 
057 AITL Male  82.13 0.62 1 0   0 1 
058 AITL Female  51.55 11.85 0 0   1 0 
059 ALCL.neg Male  58.72 0.03 1 0   0 0 
060 ALCL.neg Male  39.94 0.10 1 0   0 0 
061 ALCL.neg Male  48.66 3.04 1 0   0 0 
062 ALCL.neg Male  48.66     0   0 0 
063 ALCL.neg Male  30.86 0.08 1 0   0 0 
064 ALCL.neg Female  89.45 0.07 1 0   1 0 
065 ALCL.neg Male  77.84 2.47 1 0   1 1 
066 ALCL.neg Male  78.27 0.09 1 0   1 0 
067 ALCL.neg Male  59.82 0.79 1 0   0 0 
068 ALCL.neg Male  77.01 3.57 0 0   0 0 
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069 PTCL Male  58.33 2.11 1 0   0 0 
070 PTCL Male  75.00 10.48 0 0   1 0 
071 PTCL Male  61.40 6.33 0 0   0 1 
072 PTCL Female  46.51 0.97 1 0   1 0 
073 PTCL Female  62.38 8.66 0 0   0 0 
074 PTCL Female  59.26 5.19 0 0   0 0 
075 PTCL Male  29.42 1.08 1 0   1 1 
076 PTCL Male  63.09 2.45 1 0   0 0 
077 PTCL Male  54.50 5.57 0 0   0 0 
078 PTCL Female  55.90 0.57 1 0   1 0 
079 PTCL Male  74.28 0.62 1 0   0 0 
080 PTCL Female  67.55 18.40 1 1 T195I 1 1 
081 PTCL Male  83.69 0.29 1 0   1 0 
082 PTCL Male  66.76 0.52 1 0   0 0 
083 PTCL Male  75.29 1.49 1 0   0 0 
084 PTCL Female  88.08 2.55 0 0   1 1 
085 PTCL Female  62.86 0.75 1 0   1 0 
086 AITL Female  87.23 0.06 1 1 D124E;T195P 1 1 
087 AITL Male 51.00 0.20 1 1 D124V 1 1 
088 AITL Female 55.00 1.85 1 0   1 1 
089 AITL Female  69.82 2.15 1 1 T195P 1 1 
090 PTCL Female  81.71 14.79 1 0   0 1 
091 ALCL.neg Female 78.00 0.60 1 0   1 0 
092 AITL Male 78.00 0.07 1 0   1 1 
093 AITL Female 68.00 2.21 0 0   1 1 
094 AITL Male 48.00 0.27 1 0   1 0 
095 AITL Male 72.00 2.40 1 0   0 1 
096 PTCL Male 53.00 2.03 1 0   0 1 
097 AITL Male 69.03 2.29 1 0   0 0 
098 AITL Female 73.20 5.93 1 0   0 0 
099 AITL Female 72.96     0   0 1 
100 AITL Female 63.00     0   1 0 
101 AITL Female 77.00     0   0 0 
102 AITL Male 49.00     0   0 0 
103 AITL Female 59.00     0   1 0 
104 AITL         0   1 1 
105 AITL         0   0 0 




Patient RNA and targeted exome sequencing 
 
RNAs were extracted from the AITLs using the QIAgen RNEasy kit and analyzed by 
high-throughput RNAseq using the Illumina GIIx sequencer. TopHat147 was used for 
alignment, and Cufflinks148 was used for gene expression analysis. TopHat-Fusion149 
was used to analyze aberrant transcripts.  TopHat uses Bowtie150 as an alignment 
engineer.  Gene expression levels were calculated by Cufflinks/Cuffnorm v2.2.1 relative 
to the median of all samples.  To normalize to the T-cell signature,74,106 the mean FPKM 
values for the nine T-cell-specific genes CD2, CD3D, CD3E, CD3G, CD3Z (CD247), 
CD5, CD7, ZAP70, and LAT were calculated for each cancer sample and normal control.  
Then, the CD28 FPKM value was divided by the mean nine-gene normalization factor 
and multiplied by 100%.  For targeted sequencing, we used the TruSeq Custom 
Amplicon (TSCA) platform (Illumina, Inc.) to interrogate all four exons of CD28, all 
eleven exons of TET2, and all five exons of RHOA in PTCL specimens.  The TSCA 
approach allows sequences >600kb and up to 1,536 amplicons in a single multiplex 
reaction.  The integrated indices support sequencing up to 96 samples per MiSeq run 
(Illumina).  Alignment was performed with Mutascope,151 which takes advantage of the 
fixed start/end coordinates in amplicon sequencing to improve alignment.  VarScan2152 
was used to call variants. 
 
Table 4.  Clinical characteristics of patients in this study.  Gender, age at diagnosis, 
follow-up information, and CD28, TET2 and RHOA mutation status are indicated for the 
105 cases of AITL, PTCL-NOS, and ALK-ALCL in this study.  For follow-up status, 1 = 
deceased.  For mutation status, 1 = present. 
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Gene expression profiling (GEP) and gene set enrichment analysis (GSEA) were 
performed as described comparing CD28 WT AITL cases to AITL cases with high-
variant frequency D124 or T195 mutations. There were 178 differentially expressed 
genes found.  Gene sets are described in Figure 15. 
 
Fusion transcript validation and sequencing 
 
The ICOS-CD28 and VAV1-HNRNPM fusion mRNAs discovered on whole transcriptome 
sequencing were verified by PCR and Sanger sequencing on patient cDNA using the 
following primers: ICOS (forward): 5’-TGAACACTGAACGCGAGGAC-3’; CD28 
(reverse): 5’-CATTGGTGGCCCAACAGG-3’; VAV1 (forward): 5’- GATGCAGCAGAATT-




The Kaplan-Meier curve was constructed, and difference in survival was tested by the 
log-rank method, using the survival package in R.153 
 
Surface plasmon resonance (SPR) spectrometry 
 
Binding experiments were carried out using surface plasmon resonance as implemented 
in the BiacoreTM T200 (GE Healthcare). All analyses were performed at 37 °C. 
Analyses of the interaction between CD28 and its ligands were performed in HBS-EP 
buffer (0.01M HEPES, pH 7.4, 0.15M NaCl, 0.05% sodium azide, 0.005% (v/v) 
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Surfactant P20). Analyses of the interaction between the tyrosyl phosphopeptides of 
CD28 and SH2 domain-containing proteins were performed in a “Cytoplasmic Buffer” 
(0.01M HEPES, pH 7.4, 0.146 M KCl, 0.05% sodium azide, 0.005% (v/v) Surfactant 
P20). For determining the binding affinity of CD28 for their ligands, a blank flow cell was 
used as the control, and CD28 Fc fusion protein at 0.1 mg/ml, 10mM sodium acetate, pH 
5.0, was directly immobilized to the dextran matrix of Research Grade CM5 sensor chips 
(GE Healthcare) by amine coupling using the manufacturer’s kit (GE Healthcare) and an 
activation time of 5 min, resulting in immobilization levels of approximately 2500 RU. For 
determining the binding affinity of tyrosyl phosphopeptides of CD28 for SH2 domain-
containing proteins, biotinylated tyrosyl phosphopeptides or the universal control peptide 
(a 15-residue neutral peptide with the sequence of GSGSGSGSGSGSGSG, G = 
Glycine, S = Serine) were indirectly immobilized to the sensor surface of SA sensor 
chips (GE Healthcare) via streptavidin to levels of approximately 250 RU as previously 
described.154 Equilibrium binding analysis was undertaken as described.64,65  Briefly, 2-
fold serial dilutions of analytes were injected simultaneously over flow cells containing 
the immobilized proteins or peptides. Injections were of 30s duration, at a buffer flow rate 
of 20µl/min, which was sufficient for binding to reach equilibrium.   The binding data were 
examined using Biacore T200 Evaluation Software (GE Healthcare), and affinities were 
derived using the curve fitting tools of Origin version 5.0 (MicroCal Software Inc., 
Northampton, MA) and Microsoft Excel. 
 
Digital Droplet PCR for putative CD28 F51L mutations 
 
To determine the absolute numbers of copies of CD28-F51L and CD28-WT within our 
samples, the Bio-Rad QX200 system (Bio-Rad, Hercules, CA) was used to perform 
47 
 
digital droplet PCR in a duplex assay. Two hundred ng of genomic DNA were used as 
input, and the reaction mix was prepared according to the manufacturer’s guidelines 
(Droplet Digital PCR Applications Guide, Bio-Rad). Following droplet generation, 
samples were amplified on a Bio-Rad CFX384 Thermal Cycler with the following primer 
combination (CD28 Forward Primer: 5’-ACAATGCGGTCAACCTTAG-3’, CD28 Reverse 
Primer: 5’-CAGACTTCCACAGCACTATC-3’) in the presence of two differentially labeled 
oligonucleotide probes (WT: HEX-labeled 5’- CCCGG+A+A+CTC+CC-3’; F51L: FAM-
labeled 5’-CGG+A+G+CTC+CC-3’, where “+” indicates that the following nucleotide is a 
locked nucleic acid). Probe signals were quenched with 3’ Black Hole Quencher. The 
primers and probes were purchased from Integrated DNA Technologies (San Diego, 
CA). Data were analyzed using QuantaSoft analysis software (version 1.6.6, Bio-Rad). 
On average, 32,640 copies (range 11640 – 100200) of the CD28-WT allele were present 
in a single 20 μL reaction, whereas no copies of the mutant allele were detected.  Five 
samples with a putative CD28 F51L mutation were analyzed together with one negative 
template control, three reactive lymph node specimens, and seven cases with unknown 
CD28 mutation status. 
 
Molecular modeling of novel CD28 mutants 
 
The following PDB files were used to analyze the effects of the D124V mutation in 
CD28: 1YJD (CD28),155 1I85 (CD86 and CTLA4),156 and 1I8L (CD80 and CTLA4).157  
The amino acid change in CD28 was made in Coot158 and was modeled in each of the 
three preferred rotamers.  Each rotamer was analyzed for steric clashes with 
Molprobity159 and the Val rotamer with only one clash was selected.  The wild-type and 
mutant CD28 structures were aligned with CTLA4 in the CD86-CTLA4 structure using 
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LSQKAB160 in CCP4i161 (residues 60-118 of CTLA4 were used for the alignment).  The 
aligned CD28 structures were combined with CD86 using PHENIX.162  Interactions 
between CTLA4, CD28, and CD28 D124V and CD86 were analyzed with LigPlot+.163  
These interacting residues were used to guide the docking program HADDOCK164 to 
create docked structures of CD86 or CD80 with CTLA4, CD28, and CD28 D124V.  After 
initial rigid-body energy minimization and semi-flexible refinement in torsion angle space, 
HADDOCK performs a final refinement in explicit solvent.  This was done to more 
accurately predict the interface between CD86 and CD28 over simple rigid-body 
alignment in the absence of an experimental structure of the complex.  The docking of 
CTLA4 with CD86 demonstrated that the program could accurately recapitulate the 
experimental structure of the complex (data not shown).  Each of these docking results 
as well as the CD86-CTLA4 complex from structure 1I85 and the CD80-CTLA4 complex 
from structure 1I8L were split into the individual structures using PDBSET in CCP4i and 
the electrostatic surface potentials were analyzed with APBS165 and PDB2PQR166 using 
the APBS plugin167 in PyMOL.168 To analyze the effects of the T195P mutation in CD28, 
the crystal structure of DpYMNMT from CD28 bound to the GRB2 SH2 domain was 
used (PDB 3WA4).169 Residues Pro-Arg-Arg were added to the C-terminal end of the 
CD28 peptide and Thr195 was mutated to Pro with Coot.  The water molecules, Cd ion, 
and acetic acid molecule were removed from the PDB file and the three letter code for 
phosphotyrosine was changed from PTR to TYP, which is the code required by 
HADDOCK.  The interactions between the CD28 peptide and the GRB2 SH2 domain 
were analyzed with LigPlot+.  This revealed that the phosphotyrosine interacts with R67, 
R86, S88, S90, and S96 of GRB2, and the N193 residue of the CD28 peptide interacts 
with K109 and K120.  These residues were then used to guide docking of the 








The entirety of CD28 with or without D124V or T195P mutations was cloned into GFP-
containing pMIG-2B vectors (Promega). Retrovirus was produced in 293T cells 
essentially as described previously.170  Briefly, 2x106 293T cells were transfected with 
8μg pMIG-CD28 plasmid and 9.4μg pCL3-Ampho viral packaging plasmid by the 
calcium chloride method. Transfected 293T cells were cultured in Jurkat media (RPMI-
1640, 10% FBS, 1% 1M HEPES buffer, 1% penicillin/streptomycin) and retrovirus-
containing supernatant was collected and filtered (0.45μm). Virus and polybrene 
(10μg/mL, Sigma-Aldrich, St. Louis, MO) were used to infect ~500,000 Jurkat cells, 
clone E6.1 (ATCC).  Cells were centrifuged at 300 g for 75 minutes at 32°C. Transfected 
cells stably maintaining GFP expression after one week were sorted using flow 
cytometry. Cells were then cultured and frozen or used in the activation assay. All cell 




VAV1-variant-2 was purchased in the pOTB7 vector, and HNRNPM was purchased 
in the pCMV-Sport6 vector (Harvard Medical School, Clones HsCD00326560 and 
HsCD00321972, respectively). 





AAGG-3’.  pOTB7-VAV1 and the PCR product were digested with BamHI and AflII.  The 
resultant 4352bp and 258 bp fragments were ligated, generating pOTB7-flagVAV1. 
To generate the VAV1-HNRNPM junction, patient cDNA was amplified using the 
following primers: forward: 5’- GTTTTTCGGTCCGGATCCCTTGTAACAGGGTGAAGC-
CCTATG-3’; reverse: 5’- GCAGCTTTTTTCATGCTCTCTTC-3’, producing a 502bp 
fragment.  This fragment and pCMV-Sport6-HNRNPM were digested with RsrII and 
EcoRI, and the fragment was ligated into the pCMV-Sport6-HNRNPM vector to produce 
a 6963bp pCMV-Sport6-fusionHNRNPM intermediate. 
To create VAV1-HNRNPM, the pOTB7-flagVAV1 and pCMV-Sport6-fusionHNRNPM 
vectors were both digested with BamHI and Bsu36I, and the appropriate 2032bp and 
6894bp fragments, respectively, were ligated to produce pCMV-Sport6-flagVav1-
HNRNPM.  This served as the basis for the rest of the construct design. 
To create the final construct used in this study, VAV1-HNRNPM, VAV1-front, and 
VAV1-whole were all cloned with a triple FLAG tag on the N-terminus, and back-
HNRNPM was cloned with a triple FLAG tag on the C-terminus.  They were all inserted 
at the SalI and BamHI sites of either the pBABE-puro (gift from Hartmut Land, Jay 
Morgenstern & Bob Weinberg (Addgene plasmid # 1764)171 or the pMIT retroviral vector 
(gift of T. Mitchell)172 which has the murine Thy1.1 coding sequence downstream of the 
IRES.  Accuracy of the cloning was confirmed by Sanger sequencing. 
For pBABE-puro-based vectors, pCL3-ampho virus was packaged in 293T cells 
transfected with Lipofectamine (Thermo Scientific) per the manufacturer’s protocol, and 
the resultant virus was used to infect VAV1-null Jurkat cells (J.vav1; gift of D. 
Billadeau).173  Resistance to puromycin was selected over four weeks. 
For pMIT-based vectors, ecotropic receptor-encoding retrovirus (pBABE zeo 
Ecotropic Receptor was a gift from William Hahn, Addgene plasmid # 10687) was 
packaged in pCL3-ampho in 293T cells transfected with Lipofectamine, which was then 
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used to infect J.vav1 cells.  Resistance to Zeocin was selected over a period of four 
weeks.  Then, vectors encoding each of the four VAV constructs or empty pMIT were 
transfected by Lipofectamine into PLAT-E cells (gift of Zuoming Sun, City of Hope), and 
the resultant ecotropic virus was used to transfect J.vav1-EcR cells.  After one week, 
cells were sorted for positive Thy1.1 expression by anti-Thy1.1 antibody (APC-
conjugated, clone OX7; Biolegend), and they were sorted three more times for 
equivalent Thy1.1 levels before being frozen or used in experiments. 
 
T-cell stimulation and luciferase assay 
 
To prepare the stimulatory beads, anti-CD3 antibody UCHT1 (BioLegend, San Diego, 
CA) and either CD80-Ig or CD86-Ig (Sino Biological, Beijing, China) were ligated to 
M450 tosylated beads (Life Technologies) per the manufacturer’s instructions at a ratio 
of 1:1. In some experiments, human CD3/CD28 beads (Life Technologies) were used.  
For the NF-κB reporter assay, 6x106 Jurkat cells stably transduced with the CD28 
mutants or WT were electroporated with Photinus luciferase NF-κB reporter vector 
pGL4.32 (Promega) and the Renilla pRL-TK control vector (ratio 10:1) using the Amaxa 
Nucleofector® (program X-001). Twenty-four hours post-electroporation, the cell number 
was determined and cells were stimulated with the indicated beads at a ratio of 1:1 for 
four hours and then harvested and lysed. The dual luciferase assay from Promega was 
performed according to the manufacturer’s instructions, and luciferase activity was 






Nanostring nCounter assay 
 
To measure gene expression over time,174 one million Jurkat cells stably transduced with 
either CD28 mutants or WT, or each of the VAV-fusion-containing pMIT vectors, were 
stimulated with one million of the indicated beads for the indicated time, then 
immediately washed in PBS, lysed in Qiagen buffer RLT, and placed at -80°C until use. 
Aliquots were thawed, and 10,000 cells per reaction were prepared for nCounter 
expression analysis per the manufacturer’s instructions (NanoString Technologies, Inc. 
Seattle, WA). We designed a customized codeset panel for 29 genes and two 
housekeeping genes (Table 5). Cell lysate was hybridized to the custom codeset at 65° 
overnight. The reaction was processed on the nCounter prepstation and gene 
expression data were acquired on the nCounter Digital Analyzer on the “high resolution” 




Transduced J.vav1 cells were counted and washed with PBS, then spun against slides 
using a Cytospin in 2.5% bovine serum albumin (Sigma-Aldrich, St. Louis, MO; medium 
acceleration, 5 minutes), then fixed for 20 minutes in 4% paraformaldehyde (PFA; 
Sigma) in PBS, washed three times for with PBS.  Cells were then permeabilized for 1 
hour in 0.3% Triton-X100 (Sigma) / 0.5% BSA in PBS (TB-PBS), washed with fresh TB-
PBS, then incubated overnight at 4 degrees in the dark with rabbit anti-FLAG (Cell 
Signaling Technology, clone 2368) 1:800 in 0.5% BSA-PBS.  The next day, cells were 
washed three times in TB-PBS, then incubated for 90 minutes at room temperature in 
the dark with PE donkey anti-rabbit 1:1500 in 0.5% BSA-PBS (BioLegend, 
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Catalog#406421).  After incubation cells were washed three times in PBS then sealed 
with Prolong Gold anti-fade with DAPI (Life Technologies) and a cover slip.  Twenty-four 
hours later, slides were imaged on a Zeiss LSM-710 confocal microscope for emissions 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Flow cytometric analyses 
 
All flow analyses employed standard gating on forward- and side scatter profiles to 
ensure only data for single cells of the appropriate size were analyzed.   
For Thy1.1 expression, cells were stained for 30 minutes at 37 degrees with 1μg/mL 
AlexaFluor 647 anti-Thy1.1 (BioLegend, clone OX-7), then washed with PBS. 
For proliferation, one million cells of each cell line were incubated with CFSE (Life 
Technologies) 1:1500 for 30 minutes at 37 degrees per the manufacturer’s instructions, 
then 10,000 gated events were assessed every day for one week on an Accuri C6 (BD 
Biosciences) for emission in FL-1. 
For CD69 expression, 80,000 cells of each cell line were plated in a 96-well plate 
and stimulated for 8 hours with CD3/CD28 beads (Invitrogen) or not.  Cells were 
washed, beads removed by a magnet, then cells were stained 1:500 with anti-CD69-PE 
(BioLegend, clone FN50) for 30 minutes at 37 degrees in the dark.  Cells were then 
washed with PBS and 30,000 gated events assessed on an Accuri C6 for emission in 
FL-2. 
For VAV1 expression, one million cells were rinsed with PBS and fixed with 4% PFA 
for 10 minutes at 37 degrees, then chilled, and rinsed with PBS.  Cells were then 
permeabilized in methanol (Macron Chemicals, Central Valley, PA) for one hour on ice.  
After washing with PBS, cells were incubated with rabbit anti-VAV1 (Cell Signaling 
Technologies, #2502) 1:25 in 0.5% BSA-PBS for one hour at room temperature with 
occasional mixing.  After washing, cells were then incubated with Alexa647 goat anti-
rabbit Ig (Cell Signaling Technologies, clone 4414) 1:800 in 0.5% BSA-PBS for 30 
minutes at room temperature in the dark, then washed in PBS-2% FBS and analyzed on 
an Accuri C6 for emission in FL-4. 
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Calcium flux was analyzed essentially as described previously. Five million cells of 
each cell line were incubated with Indo1-AM (Life Technologies) 1:1000 in 100μL HBSS 
(Life Technologies) for 30 minutes at 37 degrees in the dark, then washed in PBS and 
incubated another 30 minutes at 37 degrees in the dark to cleave AM esters.  After 
washing again, cells were kept on ice until use.  Cells were collected on a BD LSR 
Fortessa using the recommended filter sets for Indo1 acquisition.  Cells were collected 
for 90 seconds to establish baseline, then stimulated for 12 minutes with 1ug/mL anti-
CD3 (BioLegend, clone UCHT1) and 1μg/mL anti-CD28 (BioLegend, clone CD28.2) 
cross-linked with rabbit anti-mouse Ig (BioLegend, clone Poly4053).  Data were binned 
for each second, and the ratio of emission at 515nm (“violet”)/395nm (“blue”) was plotted 









Detection of CD28- and VAV1-containing fusion transcripts, and 
mutations in CD28 and VAV1, through whole transcriptome 
sequencing 
 
Our analysis of WTS data from 20 AITL cases revealed a single case showing an in-
frame ICOS-CD28 fusion transcript. This fusion transcript was confirmed by Sanger 
sequencing of cDNA from the case showing a fusion of ICOS exon 1 (forward) with 
CD28 exon 2 (Figure 6A). ICOS exon 1 encodes the membrane signal sequence, but 
this is cleaved from the protein; thus, ICOS promoter-mediated expression of the 
transcript would be expected but with no change in the final product. ICOS is highly 
expressed in AITL and in TFH cells.
74 The fusion transcript was found to contain a 
mutation of aspartate 124 of CD28 to valine (D124V; Fig. 6B). This AITL case was found 
to express CD28 at a level higher than most other cases in this study; additionally, the 
AITL cases expressed CD28 at a level higher than normal T-cell subsets when  
normalized for T-cell content175 (Figure 7A). Three cases with the CD28 residue 
threonine 195 mutated to proline (T195P) with varying variant frequencies (VFs) were 
also identified. Additionally, we also found TET2 single-nucleotide variants and indels as 
reported previously126 as well as RHOA mutations.123 Based on these findings, we 
performed targeted whole-exon sequencing for CD28, TET2, and RHOA on 90 T-cell 
lymphoma cases (38 AITL – including five also having WTS, 40 PTCL-NOS, and 12 
ALK- ALCL). In 88 cases, subtype was assigned molecularly.74 For PTCL-NOS cases, 
                                                          
2
 Used with permission from Rohr et al. 2015 (reference 122) 
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GEP previously performed106 classified the cases into TBX21 or GATA3 subtypes; cases 
that did not fit into either category were considered “unclassified” (Table 6).  Clinical 
information for all cases in this study is available in Table 4. 
We also found a single VAV1-HNRNPM fusion transcript; the junction occurred 
Figure 6: Distribution of CD28 mutations discovered on transcriptome and targeted sequencing in 
T-cell lymphoma subtypes. A: Alignment of ICOS-CD28 fusion transcript and identification of 
breakpoint, verified by Sanger sequencing. B: Demonstration by Sanger sequencing of D124V 
mutant in ICOS-CD28 transcript, GAC>GTC (red box). C: Kaplan-Meier survival analysis of AITL 
cases with CD28 mutations (red) versus AITL cases with no CD28 mutations (black).  CD28-
mutant cases had inferior survival after diagnosis (p=0.005). D: CD28 map and mutations found 
in 20 AITL cases with whole transcriptome sequencing plus 38 AITL (including five cases 
overlapping with transcriptome sequencing; red), 40 PTCL-NOS (black), and 12 ALK-ALCL 
cases. SP: signal peptide; IgV: Ig variable region-like domain CD28 and CTLA4; TM: 
transmembrane domain. Yellow: “antigen-binding” site required for interaction with ligand within 
IgV domain; pink: SH2-binding motif; green: SH3-binding motifs. #: identified in whole-
transcriptome sequencing; +: identified in targeted sequencing platform. The diagram was built 




between VAV1 exon 24 (forward) and HNRNPM exon 2.  The two genes are present on 
chromosome 19 in the same orientation; an approximately 1.66Mb deletion may have 
generated the fusion.  This was validated by PCR and Sanger sequencing (Figure 8A,B).  
Other putative fusions were also identified from the WTS data (Figure 7C). 
  
Number (% of screened)   




AITL (n=53)°   3 (5.7)  3 (5.7)* 6 (11.3) 
PTCL, NOS 
(n=40) 
TBX21 (n=19) 1 (5.3) 0 1 (5.3) 
GATA3 (n=12) 0 0 0 
Unclassified 
(n=9)° 0 0 0 
ALCL, ALK- 
(n=12)   0 0 0 








CD28 mutations are relatively frequent in AITL and correlate with 
poor survival 
 
The frequencies of CD28 mutations are presented in Table 6 and Fig. 6D, and the 
TET2 and RHOA mutation status and molecular diagnosis for individual cases are in 
Table 7. Several of the mutations were verified by PCR and Sanger sequencing as 
somatic (Figure 9).  The average depth in our targeted sequencing platform was >1000-
fold, and variant frequencies for a single nucleotide polymorphism (SNP; rs3116496) 
Table 6: Recurrent mutations in CD28 in screened T-cell lymphoma cases.  Summary of 
mutations in CD28 found on targeted sequencing of PTCL cases, grouped by resultant 
mutated residue and diagnosis. Seven of 105 total cases (6.7%) had mutations at 
recurrent residues within CD28. *: this D124E case also has a T195P mutation at lower 
variant frequency; this case is only tabulated in the D124 column.  °: one case of AITL 
and one case of PTCL-Unclassified has only a histological diagnosis. 
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within the targeted region reveal a SNP proportion of approximately fifty percent (Table 
8).  Paired-end reads filtered out likely misreads, and only recurrent mutations affecting 
the same codon were identified to reduce the possibility of artifact or random calls. 
Mutations at D124 and T195 were identified by these criteria, and seven of 105 (6.7%) 
PTCL cases had a mutation at one of these residues, including 6/53 (11.3%) AITLs. Two 
mutations, both at residue T195, had VFs greater than 10% in the targeted platform 







Figure 7: FPKM of CD28 in AITL compared to non-neoplastic T-cell subtypes, 
and comparison of CD28-mutant and –WT case T-cell signature and TET2 
frequency. A: The FPKM for CD28 was calculated in each sample, and then 
samples were normalized to the T-cell signature26,32 to account for low tumor 
content in AITL. Data for normal T-cells were publicly available33. The average 
FPKM ratio for cancer samples was 31.21 (dashed line), whereas for the 
normal subtypes combined the average was 11.61 (dotted line; p<0.0001, 
Mann-Whitney test). These values are likely underestimations of the true CD28 
FPKM values in the tumor because the normalization method cannot 
distinguish the neoplastic from non-neoplastic contribution to the T-cell 
signature. B: CD28 mutation status did not alter T-cell signature (p>0.61).  C-D: 
CD28 mutation status was independent of TET2 mutant call variant frequency 
in both the targeted (C; p>0.32) and RNA sequencing platforms (D; p=0.40) 
and E-F: CD28 mutation status was independent of RHOA mutant call variant 




There was no difference in relative expression of the T-cell signature106 (Figure 7B) 
between CD28 wild-type and mutant cases in the transcriptome data. There was also no 
significant difference in average TET2 or RHOA VF based on CD28 mutation status in 
either the RNAseq or the targeted sequencing platforms (Figure 7B-D). AITL cases with 
CD28 mutations have inferior survival to CD28-WT cases (p=0.005; Fig. 6C). We also 
found apparent mutations at residue phenylalanine 51 (F51) as previously reported in T-
cell lymphomas,128 but these were all found at extremely low apparent VF (<2%) and 
could not be verified by droplet digital PCR  (ddPCR).177 
We also subjected published PTCL sequencing datasets125,127,128 to the same 
analysis pipeline and found two T195P and three F51 mutations, ranging from 2.29% to 















D124V 21.9 (Tr) 16.0 (Tr) 11.9 (Tr) 
D124E* 49.1 (Tr) 45.6 (Tr) 28.5 (Tr) 




64.2 (Tr) 50.0 (Tr) 11.2 (Tr) 
10.58 17.73 3.72 
T195P 42.7 (Tr) 28.12 (Tr) 20.6 (Tr) 
T195P 2.17 44.98 21.1 
PTCL-
TBX21 T195I 12.3 13.09 
14.4 
 
Table 7: Mutated residue in CD28 by diagnosis, variant frequency, and TET2 
and RHOA mutation status and frequency. The CD28 mutation reads are 
grouped by diagnosis. Because TET2 mutations are varied, and individual cases 
often have more than one single-nucleotide variant (SNV) or indel, only the 
presence of SNVs or indels and the highest variant frequency is shown. Variant 
frequencies are either from transcriptome (Tr) or targeted sequencing data as 




CTLA4 have recently been reported in Sézary syndrome,178,179 and a recent report on 
adult T-cell leukemia/lymphoma180 shows several mutations and fusions of CD28. We 
examined our WTS data for additional CD28 fusion transcripts but none were found. We 
also examined our NK/γδTCL data181 and found no CD28 mutations. 
 
CD28 mutant D124V has a greater affinity for CD86 than CD28 WT 
 
The D124V mutant found in the ICOS-CD28 fusion protein in an AITL case exchanges 
a negatively charged amino acid for an uncharged, hydrophobic one, and D124E (AITL) 
substitutes it for a slightly larger but equally charged R-group. These recurrent D124 
mutations are immediately C-terminal to the core of the highly conserved ligand-binding 




Figure 8.  VAV1 mutations in PTCL cases from transcriptome data. A. Alignment of 
VAV1-HNRNPM fusion, which was validated by PCR and Sanger sequencing (B).  
The distribution of VAV1 mutant calls is shown in C.  Red, AITL; black, PTCL, NOS.  
*These mutations occur in the same case at similar variant frequencies. 
VAV1 exon 1-24 HNRNPM exon 2-15















Case Call location Ref Call SNP VF Ref_F Ref_R SNP_F SNP_R 
2 chr2 204594512 T C 50.16% 310 316 315 315 
8 chr2 204594512 T C 56.84% 306 303 404 398 
10 chr2 204594512 T C 48.73% 421 425 400 404 
13 chr2 204594512 T C 49.53% 486 487 469 486 
16 chr2 204594512 T C 1.06% 558 562 6 6 
17 chr2 204594512 T C 52.50% 401 408 447 447 
18 chr2 204594512 T C 48.48% 595 593 556 562 
20 chr2 204594512 T C 49.45% 567 572 561 553 
21 chr2 204594512 T C 82.21% 582 581 2677 2696 
23 chr2 204594512 T C 52.47% 550 556 610 611 
25 chr2 204594512 T C 46.02% 610 603 518 516 
27 chr2 204594512 T C 99.83% 4 4 2334 2350 
31 chr2 204594512 T C 48.30% 840 859 788 799 
33 chr2 204594512 T C 52.87% 545 539 605 611 
36 chr2 204594512 T C 57.89% 519 519 703 724 
40 chr2 204594512 T C 55.23% 505 501 620 621 
41 chr2 204594512 T C 55.30% 506 519 634 634 
42 chr2 204594512 T C 51.41% 677 688 721 723 
48 chr2 204594512 T C 59.95% 522 526 786 783 
51 chr2 204594512 T C 99.83% 6 4 2993 3008 
63 chr2 204594512 T C 43.16% 1803 1800 1368 1368 
65 chr2 204594512 T C 97.69% 3 3 124 130 
66 chr2 204594512 T C 51.62% 616 620 654 665 
67 chr2 204594512 T C 46.52% 1197 1200 1040 1045 
73 chr2 204594512 T C 99.42% 4 4 681 693 
75 chr2 204594512 T C 99.79% 3 4 1629 1630 
76 chr2 204594512 T C 13.69% 2246 2237 356 355 
80 chr2 204594512 T C 54.84% 305 311 373 375 
83 chr2 204594512 T C 72.20% 288 292 755 751 
92 chr2 204594512 T C 56.56% 392 399 517 513 
93 chr2 204594512 T C 50.93% 1075 1063 1106 1113 
95 chr2 204594512 T C 59.31% 271 269 394 393 
Table 8: Targeted sequencing SNP calls.  For the cases with SNP rs3116496 (which is 
within an intron of CD28; Chromosome 2, position 204594512, T>C), the variant frequencies 
for most SNP calls were at approximately 50% or 100%, likely indicating the presence of the 






Figure 9. CD28 variants are somatic mutations.  A-C: Three additional putative CD28 
mutations were subjected to Sanger sequencing.  T195P (A, C) and D124E (B) all had the 
expected mutant calls at a frequency <<50%, indicating that these variants are somatic in 










































































































































































































































































































































































































































































































































CD28 mutant D124V has a greater affinity for CD86 than CD28 WT 
To assess whether D124 mutations affect the affinity of CD28 for its physiological 
ligands, we selected the CD28 D124V mutant for surface plasmon resonance (SPR)-
based analysis of the binding affinity of CD28 for its ligands. Representative binding 
curves and Scatchard plots for determination of experimental Kd and Ka are shown in 
Figure 10A-D. The affinity of CD28 D124V for CD86 was an average 2.6-fold higher than 
that of CD28 WT (Fig. 10E; p < 1x10-5 for 6 replicates), whereas CD80 binding affinity 
was not significantly different. 
To understand why CD86 has a greater affinity for the CD28 D124V mutant than for 
CD28 WT, we modeled their interaction (Figure 11). Because a complete crystal 
structure of CD28 bound to ligand is not available, we used the crystal structures of the 
CD28 extracellular domain155 and the complex between CD86 and CD28 family member 
CTLA4.156 In this model, the protein surface in the vicinity of the D124V mutation has a 
more positive overall charge compared to CD28 WT and more closely resembles the 
surface charge of CTLA4 (Fig. 11C, F, I), which binds CD86 with a 20- to 100-fold 
greater affinity than CD28.66-68 This is possibly because the negatively charged D124 
counters any surrounding positive charges, leading to a neutral surface on CD28 WT. 
The D124V mutant is therefore expected to interact more strongly with the negatively 
charged pocket of CD86 (Fig. 11A, D, G, black dashed outline). Thus, the increased 
affinity of the mutant may result from improved charge complementarity. Furthermore, 
several residues, notably in the ligand-binding site, are rotated compared to CD28 WT. 
This is likely a result of the improved electrostatic interactions with the mutant CD28, 
leading to a better packing of the interface. We also performed molecular modeling on 
the CD80-CD28 interaction (Figure 12; Table 10) in the same manner using the crystal 
































































































































































































































































































































































































































































































































CD28 mutant T195P has a higher affinity for GRB2 and 
GADS/GRAP2 than the CD28 WT 
The T195P mutation changes a polar amino acid to a hydrophobic one at the residue 
between the YMNM-containing SH2-binding motif and proximal PxxP-containing SH3-
binding motif, essential mediators of adaptor protein binding during downstream 
signaling.182 This mutant of CD28 is predicted to have a higher affinity for GRB2 than WT 
according to ScanSite.183 To examine experimentally whether T195P alters the affinity of 
CD28 for adaptor proteins, we determined the affinity of this form of CD28 for several 
SH2 domains in known binding partners (Fig. 9). For two replicates, only GADS/GRAP2 
and GRB2 showed significant differences, so each was assayed six more times. The 
CD28 T195P mutant had an average 1.7-fold greater affinity for GADS/GRAP2 and a 
2.0-fold greater affinity for GRB2 than the CD28 WT (p < 1x10-5 for both). 
No complete crystal structure of the CD28 cytoplasmic domain is available, and it is 
likely intrinsically disordered.  However, there is one model of a synthesized (non-native) 
CD28 phosphotyrosine motif interacting with the SH2 domain of the adaptor protein 
GRB2,169 which we employed to build our model. The CD28 T195P mutation, which 
alters the lone residue between the SH2- and proximal SH3-binding motifs, was 
predicted to modify the conformation of the cytoplasmic tail C-terminal to the mutation 
(Fig. 10J-L). Interestingly, the HADDOCK model164 predicts that the interaction with 
GRB2’s SH2 domain is not directly altered. Rather, P196, within the adjacent SH3-
binding motif, contorts significantly, potentially increasing the interaction between the 
CD28 P196 Cβ and Cδ atoms and the side chains of GRB2 R142 and N143, respectively. 
Comparing wild-type CD28 to the T195P mutant, the distance between P196 Cβ and the 
closest guanidino [-NHC(=NH)NH2] group of GRB2 R142 is essentially unchanged (4.5 




































































































Figure 11: Protein modeling of CD28 WT and D124V interacting with CD86, and CD28 WT 
and T195P interacting with GRB2. A-I: PyMOL models of CD86 bound to receptor CTLA4, 
CD28 WT, or CD28 D124V with APBS-generated electrostatic surfaces. A-C: CD86-CTLA4 
interaction. The residue corresponding to D124 in CD28 (L141) is indicated in C and the 
protein surface in the vicinity of this residue has an overall positive charge (also apparent in 
B). The negatively charged binding surface of CD86 can be seen in A (dashed line and 
surrounding area). D-F: CD86-CD28 WT interaction. The surface around D124 is more neutral 
compared to CTLA4. G-I: CD86-CD28 D124V interaction. Replacement of the negatively 
charged aspartate residue leads to a more positively charged surface, similar to CTLA4. The 
orientation of several residues is changed (Y118 – red arrow, P121 – black arrow) between 
CD28 WT and CD28 D124V in these models. J-L: PyMOL models of the CD28 cytoplasmic 
tail with or without the T195P mutant binding adaptor protein GRB2. J, L: CD28 WT (J) and 
T195P (L) cytoplasmic tail binding GRB2 (J, salmon; L, chartreuse). T195 is colored black (J); 
T195P is colored yellow (L). Note the distances between CD28 P196 carbons Cβ (black dotted 
circle) or Cδ (black dashed circle) and the closest non-hydrogen atoms on GRB2 (red arrows). 
CD28 P196 Cβ moves from 10.6Å away from GRB2 N143 in the CD28 WT to 6.9Å in CD28 
T195P. K: Overlay of CD28 WT versus T195P mutant binding of GRB2. There is a significant 
change in orientation of several CD28 residues: proximal SH3-domain P196 (purple arrow) 
rotates and approaches GRB2 N143 in the CD28 T195P mutant. GRB2 R142 and N143 have 
a strikingly different rotation in the CD28 T195P mutant compared to WT (red dashed circle). 
 
GRB2 N143 decreases from 10.6 to 6.9Å, drawing it close enough to interact. Given the 
lack of constraints in this model that would be imposed by the remainder of the CD28 
tail, these results must be interpreted with caution; however, they do provide a plausible 
explanation for the altered affinity. 
 
VAV1 mutations: predicted affinity differences 
 
The various apparent VAV1 point mutations (see Fig. 8) were not predicted to have 
any differential binding by ScanSite.183  However, the VAV1-HNRNPM fusion was 
predicted to have an additional, high-affinity site for binding PLCG1, suggesting that the 
mutant may have a novel mechanism of activating PLCG1.  This interaction could not be 
modeled because HNRNPM has no solved structure, and even by homology its structure 







Figure 12. Molecular modeling of CD80 interacting with CTLA4, CD28 WT, and 




anchored intrinsically.  It is possible that HNRNPM is largely intrinsically disordered and 
can only hold a structure when in complex with nucleic acid through its RNA recognition 
motifs (RRMs). 
Considering that the VAV1 point mutations only occurred in one case each, there are 
wide potential differences in affinities for binding partner through each unique site.  




Figure 12: Molecular modeling of CD80 interacting with CTLA4, CD28 WT, and CD28 D124V. 
A-I: Surface diagrams of modeled interactions between CD80 and B7 family members as in 
Fig. 11. J-O: Cartoons of the same interactions; italicized and non-italicized labels indicate 
residues in CD28 or in the B7 family member, respectively. There are several notable 
differences between the CD80-CD28 WT interaction and that of CD80 and CD28 D124V. 
First, the surface of CD28 D124V near the mutated residue (Fig. 12I) is remarkably positively 
charged (bottom right), whereas in CD28 WT, the corresponding surface near residue D124 is 
more neutral (Fig. 12F). Upon examination of the residues interacting with D124 in CD28, the 
closest nitrogen (Nζ) of lysine 127 was found to be 2.1Å away from the oxygen group in D124 
(Fig. 12K), likely due to electrostatic interaction and hydrogen bonding between the two side 
chains.  The positive lysine approaching the negative aspartate cancels out both charges, 
leading to the neutral surface seen in the model. In CD28 D124V, the Nζ of K127 is 12.7Å 
from the closest carbon in V124 (Fig. 12L); as valine is hydrophobic, the positively charged 
lysine is repelled.  This represents another significant difference. In CD28 WT, the amino 
nitrogen of K20 is 6.9Å from the closest oxygen of D124, whereas it is 5Å from the closest 
carbon atom in D124V despite the loss of electric attraction in the hydrophobic valine.  This 
appears to be due to the electrostatic repulsion and/or steric hindrance from the attracted 
K127 in CD28 WT. Thus, K20 contributes to the positive surface charge in CD28 D124V 
described above, whereas in CD28 the charge is mitigated by D124. Additionally, this 
movement of K20 makes it closer to E81 in CD80 in the CD28 D124V mutant compared to the 
WT (6.0 vs. 9.8Å), suggesting additional electrostatic stabilization in the interaction of the 
mutant. CTLA-4 does not have a positively charged residue in the equivalent location. 
Comparing the interacting residues near and within the MYPPPY “antigen-binding” site of 
CD28 WT, CD28 D124V, and CTLA4 interacting with CD80, CTLA4 and CD28 D124V are 
more similar in distance from CD80 than CD28 WT (Table 1; Fig. 12M-O).  Also of note, 
compared to the most negatively charged interaction surface of CD86 (Fig. 11), the 
corresponding surface of CD80 is notably more neutral or tending toward positively charged 
(Fig. 12A, D, G). This suggests a different mechanism for the improved activation of CD28 










     
   
Distance (Å) from CD80 atom 





K20-Nζ E81-O Hydrogen bond   9.8 6.0 
M117(134)-Sδ R92-NH Hydrogen bond 4.4 3.8 3.4 
P121(138)-Cγ K36-Cγ Dispersion forces 5.1 6.2 4.6 
P121(138)-Cγ K36-Cδ Dispersion forces 4.6 5.7 3.7 
Y122(139)-OH R94-N1 Hydrogen bond 4.1 5.8 5.3 
L123(Y140)-Cδ K36-Cδ Dispersion forces 4.5 7.2 3.2 
L141-Cδ 
E81-O 
Dispersion forces 9.1     
D124-O Hydrogen bond   9.4   
V124-Cγ Dispersion forces     7.7 
      Intramolecular 
measurements 
     
   
Distance (Å) from Atom 2 






D124-O Hydrogen bond   6.9   
V124-Cγ Dispersion forces     5.0 
K113(130)-Nζ 
L141-Cδ Dispersion forces 5.5     
D124-O Hydrogen bond   2.7   
V124-Cγ Dispersion forces     7.1 
Y122(139)-Cε 
L141-Cδ Dispersion forces 5.1     
D124-Cβ Dispersion forces   4.8   
V124-Cγ Dispersion forces     3.7 
K127-Nζ 
D124-O Hydrogen bond   2.1   
V124-Cγ Dispersion forces     12.7 
 
Table 10: Inter- and intramolecular distances in the CD80-CTLA4, CD80-CD28WT, 
and CD80-CD28D124V interactions models. The distances between interacting 
atoms were calculated in PyMOL. 
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CD28 mutants alter transcription and induce higher NF-κB pathway 
activation than CD28 WT 
 
To determine whether these mutations alter the kinetics or magnitude of CD28 
signaling, we examined the expression of transcripts previously determined to be 
regulated upon CD28 ligand binding in Jurkat and/or CD4+ T-cells.184 Jurkat cells 
transduced with CD28 WT or mutants with similar levels of expression (Figure 13) were 
incubated for the indicated times with beads ligated with anti-CD3 antibody and CD86. 
CD28-positive Jurkat cells were chosen instead of CD28-null for this experiment to best 




Figure 13: GFP expression in CD28 mutant- or WT-expressing Jurkat cell lines.  Jurkat cells 
retrovirally transfected with pMIG-CD28 plasmids as described in the Materials and Methods 
were assessed for GFP expression by flow cytometry on an Accuri C6 cytometer.  
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Expression profiles were similar among the samples (Figure 14A); the Nanostring 
method, which directly counts the number of transcripts in a given sample, was chosen 
because it has greater reproducibility than qPCR.174 Two of the assayed genes, CD226 
and TNFA, showed upregulation in CD28 T195P over WT (Fig. 14B, 14C). No assessed 
transcript was significantly different between CD28 D124V and WT. 
An NF-κB reporter vector was transfected into these Jurkat cells, and the cells were 
exposed to beads coated with anti-CD3 and either CD80 or CD86 (Fig. 14D). Compared 
to Jurkat cells transduced with CD28 WT, D124V showed a 1.9-fold greater NF-κB 
induction in response to CD80 and a 1.7-fold greater induction to CD86. T195P showed 
1.5-fold and 1.8-fold higher NF-κB induction to CD80 and CD86, respectively. The 
increase in activation by the D124V mutant did not significantly differ between CD80 and 
CD86, an unexpected finding given the difference seen in the SPR (Fig. 10). We also 
compared the GEPs of the six CD28-mutant AITL cases to those of CD28 WT AITL 
cases and found 178 differentially-regulated genes (Figure 15A). Gene set enrichment 
analysis (GSEA) showed several differentially regulated pathways, most notably an 
increased T-cell signal transduction signature in CD28 mutant cases and a higher B-cell 












































































































VAV1-HNRNPM fusion protein characterization 
 
To understand the function of the VAV1-HNRNPM fusion protein, the entire fusion 
protein was cloned.  For controls, VAV1 only N-terminal to the junction (Vav1-front), the 
entirety of VAV1 (VAV1-whole), or HNRNPM C-terminal to the junction (back-HNRNPM) 
were also cloned (Figure 16).  The VAV1-containing constructs have a triple FLAG tag 
on the N-terminus; the HNRNPM-only construct has a triple FLAG tag on its C-terminus.  
The pBABE-based vectors were stably transfected into J.vav1 cells (a VAV1-null 
derivative of the Jurkat T-cell line), and cells were stained for the location of the FLAG 
tag (Figure 17).  VAV1-HNRNPM showed mostly cytoplasmic staining with some nuclear 
puncta, suggesting primarily cytoplasmic localization.   
The pBABE-puro constructs unfortunately progressively lost FLAG signal over 
several passages while retaining resistance to puromycin selection, so the constructs 
were recloned into the pMIT vector and selected based on quantity of murine Thy1.1 
expression (Figure 18) for the remaining functional analyses.  Each has only one or two 
replicates, so results must be interpreted cautiously. 
 
Figure 14. CD28 D124V and T195P mutants alter transcriptional profiles and increase NF-κB 
signaling in response to CD28 ligation. A: Jurkat cells stably transduced with GFP-containing 
retroviral constructs expressing CD28 WT or mutants were stimulated with beads ligated with 
anti-CD3+CD86 for the indicated time, and specific transcripts were quantitated using the 
Nanostring nCounter. The heat map was constructed from comparative expression profiling of 
the indicated genes. B-C: Two transcripts, CD226 and TNFA, showed significantly increased 
expression in cells expressing the CD28 T195P mutant. *: p<0.05 between T195P and WT; 
***: p<0.005 between T195P and WT. There is no significant difference between the D124V 
and WT. D: Luciferase reporters of NF-κB activation were transduced into Jurkat cells 
expressing the indicated CD28 transgene and stimulated with the indicated beads for four 
hours. Diagram averages three replicates. *, p<0.05; **, p<0.01; ns, not significant. Both CD28 








Figure 15: Gene expression profiling (GEP) and gene set enrichment analysis 
(GSEA) on CD28 mutant versus CD28 WT AITL cases.  AITL cases with a high 
expression of D124 or T195 mutations (6 total) were compared to CD28-WT 
AITL cases.  A: There were 178 genes with significant differential expression, 
p<0.005.  B-G: GSEA on the expression profiles of CD28-mutant versus CD28-
WT cases. Notably, the T-cell signal transduction signature (B) was 
overexpressed in the CD28 mutant group, as was the metastatic signature 
(C), the TGFβ pathway (D), and the stem cell signature (E).  F-I: CD28 mutant 
cases underexpressed the IFNγ signaling, IL4 signaling, antigen processing, 

















J.vav1 cells transfected with constructs or empty control, or the WT Jurkat, were 
assessed for proliferative capacity by carboxyfluorescein succinimidyl ester (CFSE) dye 
dilution (Figure 19).  The fusion-containing cells have slightly higher fluorescence levels 
at later timepoints, suggesting a slightly lower proliferation level, and all J.vav1 cell lines 
had lower proliferative capacity than Jurkat.  Notably, expression of WT VAV1 in J.vav1 
cells did not reconstitute the proliferation seen in Jurkat. 
These cells were also assessed for capacity to upregulate CD69, a marker of 
activation, during stimulation.  The fusion-containing cells had lower CD69 expression at 
24 hours of stimulation than cells expressing the other constructs (Figure 20). 
Expression of VAV1 was assessed by intracellular flow cytometry.  VAV1 was seen 




Figure 16. VAV1-HNRNPM construct and controls.  Domain names and 
amino acid positions are indicated.  The three VAV1-containing constructs 
have a triple FLAG tag on the N’-terminus; the back-HNRNPM construct 









The importance of VAV1 in the initiation of calcium flux in T-cell activation is well-
described, and the VAV1-HNRNPM fusion has a high predicted affinity for PLCG1 via a 
site on HNRNPM (see “VAV1 mutations – predicted affinity differences).  Therefore, 
calcium flux in stimulation was assessed by flow cytometry.  For two replicates, very little 
difference was seen, with the fusion-containing cells fluxing faster than empty vector but 
slower than other transfected cells (Figure 22). 
To assess the effects of the fusion on transcription, cells were stimulated for 8 hours 
then interrogated using the Nanostring codeset described above.  For one replicate, 
several genes were significantly upregulated compared to controls (Figure 23).  Notably, 
 
Figure 17.  Cellular localization of VAV1-HNRNPM and related constructs using the FLAG tag.  
A-B. IDH2-FLAG Jurkat cells (A) stain in their mitochondria, and J.vav1 cells (B) have no 
staining.  C. VAV1-HNRNPM cells have mostly cytoplasmic FLAG expression with distinct 
nuclear puncta.  VAV1-front cells (D) and back-HNRNPM cells (F) have pancellular expression, 





CCL4, CD69, CD83, IER3, LTB, TIEG, TNFAIP3, and TNFA, all of which are early 
activation response genes, have a large number of reads in the VAV1-HNRNPM 
sample, higher than the Jurkat Vav1+ control.  The VAV1-whole and VAV1-front control-
expressing cells also have higher expression of many of these than Jurkat, and usually 

















Figure 18. Thy1.1 expression of VAV1 
constructs.  Each transfected J.vav1 
line has similar Thy1.1 levels.  






Figure 19.  CFSE proliferation assay. Cells of each line 








Figure 20.  Increased expression of CD69 in response to stimulation.  Transfected cells plus 
wild-type Jurkat were stimulated for zero (A), 5 (B) or 24 (C) hours with CD3/CD28 beads, and 
surface expression of CD69 was assessed by flow cytometry. 
A B C
 
Figure 21.  Intracellular expression of VAV1.  Cells were 


































































Figure 22.  Changes in expression of TCR-upregulated genes over time.  Transfected cells or 
wild-type Jurkat were stimulated or not for 8 hours with CD3/CD28 beads, and RNA levels 
were directly assessed.  The VAV1-HNRNPM cells (red square and upright blue triangle) 
notably upregulated many targets higher than Jurkat (blue circle and brown square), 
including CD69, and IER3.  The VAV1-whole and VAV1-front controls, however, upregulated 
most of the targets greater than Jurkat as well. 
Figure 23.  Calcium flux.  Transfected cells or wild-type Jurkat were stimulated and degree of 
calcium flux was measured.  Jurkat cells (top blue line) show the expected kinetics and 
degree of flux.  Empty vector and EcR-transfected J.vav1 cells (bottom orange circle and gray 
crosses, respectively) show characteristic delay of influx and lower maximum levels, plus low 
sustainability.  Cells with VAV1-front and VAV1-whole (green triangle and purple “X”, 
respectively) have a similar early kinetic profile to Jurkat cells but cannot sustain the influx.  
Cells with VAV1-HNRNPM and back-HNRNPM display an intermediate kinetic profiles.  
Average of two replicates, normalized to baseline values. 
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CD28 and VAV1 mutations 
 
Gene expression profiling analysis has pointed to a strong T-cell receptor signal in 
peripheral T-cell lymphomas, both for AITL and PTCL, NOS.  This work explores the 
outcomes of mechanisms by which increased or constitutive activation of the T-cell 
receptor pathway may occur: mutation of proximal signal molecules.  Sequencing data 
on 105 PTCL, NOS and AITL cases showed a fusion and recurrent mutations in CD28, 
the canonical T-cell co-stimulatory receptor, as well as several mutations and a fusion in 
VAV1.  These molecules sit at the earliest stages of signal transduction through the 
TCR, and in both cases, their proper function is necessary to propagate and sustain T-
cell activation.  Recent sequencing studies on PTCLs, particularly AITL, have shown 
frequent mutations in RHOA and in the epigenetic modifiers TET2, DNMT3A, and IDH2, 
as well as less frequent mutations affecting TCR signaling proteins, including FYN. Our 
study finds similar frequencies and locations of TET2 mutations in AITL and other types 
of PTCL as previously determined, and we show that the less frequent CD28 mutations 
may play a role in promoting TCR and NF-κB signaling. 
CD28 is the canonical co-stimulatory receptor which is activated by B7-family ligand 
while MHC binds the CD3/TCR complex with co-receptor CD4 (or CD8, though for the 
purpose of the diseases discussed in this thesis, CD4 is the operative molecule).  Upon 
ligation, the CD28 intracellular domain’s SH2- and SH3-binding motifs bind and a 
                                                          
3
 Sections of the discussion are based on Rohr et al. 2015 (ref. 122) 
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multitude of signaling proteins, notably, GRB2, PI3K, ITK, LCK, PKCθ, and FYN.  These 
activated intermediates initiate major shifts in cellular metabolism, motility, and 
transcription status in concert with CD3/TCR activation.  Although the TCR provides the 
major stimulatory signal, co-stimulator activation is required to maintain activation and 
allow the T-cell to assume its effector function.  Co-inhibitory B7 family receptors, 
including CTLA4 and PD1, among others, compete with CD28.  In addition to directly 
competing for ligand, the B7 family co-inhibitors can decrease CD3/CD28 signaling 
through direct and indirect interaction with signaling intermediates. 
The cancer samples in this study show recurrent mutations of CD28 at two residues: 
aspartate 124, which is immediately adjacent to the six-amino acid MYPPPY “antigen-
binding” motif, and threonine 195, which is between the SH2- and N-terminal SH3-
binding motifs.  One mutation at each residue (D124V and T195P) was found to have a 
higher affinity for binding partner by SPR and each was found to induce higher NF-κB 
activation than CD28 WT when stimulated.  For T195P, there were also notable 
transcriptional differences upon activation.  The interactions were modeled to identify the 
potential mechanism by which the increased affinity may occur. 
The fusion transcript between ICOS and CD28 is driven by the ICOS promoter, most 
likely as a result of partial tandem duplication of the CD28-ICOS-CTLA4 locus. Because 
ICOS is highly expressed in AITL, it is expected that this fusion can drive higher CD28 
expression (Figure 7). However, the signal peptide, encoded by the first exon of ICOS, is 
cleaved from the final protein, such that the product only contains CD28 with the 
mutation. Recently reported cases of Sézary syndrome had a CTLA4-CD28 fusion, 
whose expression is expected to be driven by CTLA4; in this case, the extracellular 
domain of CD28 is replaced by CTLA4, which augments CD28 intracellular signaling 
through the higher-affinity CTLA4 extracellular domain.178,179 A study on adult T-cell 
leukemia/lymphoma found rare CD28 D124, T195, and F51 mutations, ICOS-CD28 and 
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CTLA4-CD28 fusion transcripts, and copy number increases of CD28.180 Although we 
found no CTLA4-CD28 fusions, we show that enhanced CD28 pathway activation can 
be achieved also through mutation. The D124V mutant, which occurs adjacent to the 
extracellular ligand-binding site, has an increased affinity for ligand CD86 shown by 
modeling and SPR analysis (Figures 10 and 11). Our modeling of the interaction 
between CD86 and CD28 indicates that the increased affinity of the D124V mutant is 
likely due to improved electrostatic interactions as opposed to steric or hydrophobic 
factors. There is also evidence of enhanced downstream target activation. The fact that 
the D124V mutant has the same NF-κB activation with either CD80 or CD86 stimulation 
is unexpected based on the binding analysis (Fig. 14) which shows CD86, but not CD80, 
having a higher affinity for the D124V mutant. The model of the CD80-CD28 interaction 
shows several interactions that could explain these findings (Fig. 12). On the cell 
surface, the orientation of CD28 homodimers is highly constrained, whereas in the SPR 
flow cell, they are three-dimensionally unconstrained. Three-dimensional Ka 
measurements by SPR of TCR/MHC interactions are approximately 1000-fold lower than 
the same analysis in two dimensions. Thus, it is possible that a difference in affinity for 
CD80 between WT and mutant CD28 when confined to the plasma membrane may not 
be apparent by SPR analysis. Also, crystal structures of the modeled complexes would 
be useful, as they may reveal changes not predicted by the molecular modeling. 
Interestingly, CD28 expression in multiple myeloma has been shown to alter 
myeloma proliferation and survival,185 and to be predictive of disease progression and 
relapse in conjunction with CD86, but not CD80, expression.186,187 
There are several possible mechanisms by which increased ligand affinity may 
augment CD28 signaling. First, the increased affinity for SH2-containing adaptor proteins 
may directly increase CD28 signaling. Another possibility is through reduced receptor-
mediated endocytosis. The PI3K regulatory subunit’s SH2 domain binds to the 
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phosphotyrosine motif of the CD28 cytoplasmic tail and effects a wide range of changes, 
including CD28 receptor internalization. Our binding assays show no significant 
difference between the CD28 WT and CD28 T195P binding of PI3K regulatory subunits 
(Fig. 10). Because GRB2 and GADS/GRAP2 have a significantly higher affinity for the 
T195P mutant tail over WT, perhaps these adaptor proteins outcompete PI3K for binding 
to the CD28 SH2-binding motif and thereby compromise CD28 endocytosis. A 
decreased downregulation of CD28 signaling would have the same effect as direct over-
activation, e.g. to augment cell cycling, proliferation, and cytokine production. 
Analysis of gene expression using nCounter (Fig. 14) showed enhanced 
upregulation of two CD28-responsive genes, CD226 and TNFA, by CD28 T195P 
compared to WT. CD226 is crucial for TFH differentiation and can significantly modulate 
T-cell function by outcompeting its inhibitor TIGIT to bind receptor CD155.188 TNFA is a 
potent cytokine that enhances proliferation, in part by inducing IκB-kinase 
phosphorylation and NF-κB activation.189 It is also interesting that CD28-mutant AITL 
cases showed upregulation of the T-cell signal transduction signature over CD28 WT 
AITL cases (Fig. 7). One major consequence of TCR/CD28 signaling is the activation of 
the NF-κB signaling pathway, and both mutants demonstrate enhanced NF-κB activity 
using a luciferase reporter assay. Taken together, these data support the notion that the 
two CD28 mutations explored in this study may impart a functional advantage to CD28-
mutant T-cells. 
One other mutation hotspot in CD28 was identified in our screen, as found in 
previous studies: phenylalanine 51, which we found to be mutated to leucine or valine.  
However, these cases had extremely low variant frequency in the sequencing platform, 
and none of the mutations were able to be verified by digital droplet PCR.  Other studies 
have also identified F51 mutations in PTCLs, including Sézary syndrome,179 ATLL,180 
and AITL,128 and we also found these mutations using our analysis pipeline (Table 9); 
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mutation of F51 was found to increase proliferation in a CTCL model.179  Thus, despite 
the negative PCR data, it seems plausible that the F51 mutations are real but subclonal.  
Still, we cannot be certain. 
The clonality or subclonality of various mutations in lymphoma is important for 
considering how cancers can become resistant to treatments.  In the natural history of 
many cancers, including AITL and PTCL, NOS, there is often an initial response to 
chemotherapy resulting in decreased tumor size on imaging, but frequently cancers 
evolve to be resistant to treatment.  As discussed in “Treatment and outcomes,” PTCLs 
tend to relapse, often within the first few months after treatment begins.  It is likely that 
relapse is caused by some subclone within a cancer which has a survival or proliferation 
advantage that allows it to grow even in the presence of the chemotherapy.  We hypo-
thesize that activating mutations of CD28 may give a clone a survival advantage, and 
thus be the population that survives chemotherapeutic insult.  The only way to test this 
would be to have more samples.  Ideally, there could be serial samples from the same 
patient to track mutational changes as has been done in diffuse large B-cell lymphoma190 
and others.  A good start would be to get at least some samples that are known relapse 
after clinical remission.  However, standard-of-care does not include rebiopsy for PTCLs 
unless there is clinical suspicion of a different malignancy or other concern, so there 
needs to be a concerted effort to collect and sequence relapsed PTCL cases in order to 
test whether CD28 or any other mutation is tied to risk of an event after treatment.  
This study also finds and validates a gene fusion in which VAV1 participates, and 
identifies several putative mutations from WTS and WES data.  GRB2, LCK, FYN, and 
other early TCR intermediates such as LAT and SLP76 directly or indirectly activate 
VAV1, a guanine exchange factor (GEF) that activates Rho family members including 
CDC42, RAC1, and RHOA, which regulate a multitude of intermediates in later signal 
transduction.  Particularly, VAV1 is important in actin remodeling, calcium flux, and a 
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variety of pathways leading to transcriptional upregulation of activation-induced 
cytokines and other proteins via NFAT and NF-κB, among others.  There are three VAV 
family proteins, but VAV1 is the most specific to, and most important for, the 
hematopoietic system. 
Adult T-cell leukemia/lymphoma (ATLL), another PTCL subtype with fairly poor 
prognosis, has a well-defined, almost exclusive, association with infection by the human 
T-lymphotrophic retrovirus (HTLV-1).  It is characterized by high TCR activation levels as 
well.  As discussed above, a recent study examining an extremely large cohort (n=426) 
found great numbers of mutations throughout the genome.180  Notably, ATLLs had a 
variety of mutations within TCR-associated proteins, many of which are or are predicted 
to be activating.  There were also several fusion proteins involving the B7 family 
receptors CTLA4, CD28, and ICOS, all of which put the activating CD28 cytoplasmic 
domain under control of promotors of the inhibitory CTLA4, and increased copy number 
of CD28.  There were also several recurrent mutations in VAV1 and PLCG1 which likely 
also function to positively regulate signaling.  Why another AITL study in addition to this 
ATLL study found PLCG1 mutants whereas our samples had none is unclear.  Possibly 
it has to do with the geographic and ethnic differences among the various populations as 
well as inherent differences between different subtypes of PTCLs.  Further, one study 
found a high proportion (ten percent of their cohort) of CTLA4-CD28 fusions in various 
PTCL entities.191  This number, frankly, seems too high considering that all other studies, 
including this dissertation, report no more than two percent of cases having CD28 
fusions; we have submitted a letter to the editor analyzing all available datasets and 
finding significantly fewer fusions than implied by that study.192 
 
VAV1 was among the first GEFs identified, and its functional domains among the first 
assessed.  VAV1 has a complex autoinhibitory mechanism by which its double 
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homology (DH) domain, a major catalyst for GEF activity, is inhibited by its neighboring 
acidic (Ac) domain, and phosphorylation of tyrosine 174 in the Ac domain in early TCR-
mediated activation relieves this autoinhibition on the DH domain, eventually allowing 
the RhoGEF domain to exchange guanine.  This autoinhibitory mechanism is 
augmented by interactions with the C-terminal SH3 domain, which is also relieved by 
indirect phosphorylation through TCR activation.  Mutation or deletion of the C-terminal 
SH3 domain, therefore, prevents this secondary step of auto-inhibition thereby leading to 
increased activation.  This indeed appears to be the case in ATLL, where the majority of 
VAV1 mutations are either within the Ac domain or clustered in the C-terminal SH3 
domain, though there are other hotspots as well. 
The VAV1-HNRNPM fusion found in this study eliminates the entire SH3 domain, 
and other putative mutations may have other effects on the various domains in which 
they take part.  At the time of writing we are attempting to confirm the presence of these 
mutations by whole-exome sequencing.  Should they prove to be real, their function will 
need to be assessed to determine whether they can alter downstream pathway 
activation and then lead to or propagate cancer.  Preliminary work on the VAV1-
HNRNPM mutation suggests that the fusion protein can translocate to the nucleus, likely 
via its somewhat cryptic nuclear localization sequence.193  Although the effects on CD69 
expression, a marker of activation, were minimal by flow cytometry (Fig. 19), there does 
indeed appear to be greater positive transcriptional effects of the mutant compared to 
the WT VAV1 in CD3/CD28 stimulation, including CD69 specifically (Fig. 23).  These 
each are, however, for a single biological replicate, so more data must be collected in 
order to assert whether the findings are true. 
For the short-term future experiments, confirming and expanding the findings in the 
VAV1 fusion study will be necessary to decide whether the fusion is of consequence.  In 
the longer term, the function of the putative VAV1 mutations needs to be assessed 
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should they prove to be true.  Given the preponderance of mutations throughout VAV1 in 
ATLL, it follows that the apparent mutations in AITL and PTCL, NOS, if they are true, are 




The mutations in AITL and PTCL, NOS must cooperate 
 
TET2, IDH2, and DNMT3A mutations in AITL and PTCL, NOS are discussed at 
length in “Genetic origins.”  We found the expected overall and variant frequencies of 
TET2 mutations; IDH2 and DNMT3A mutations for these same cases are reported in 
Wang et al. 2015.  Given that each of the other mutations exists nearly exclusively in the 
background of TET2 loss-of-function, there must be a degree of either cooperativity 
between the later mutations and TET2 LOF, or the loss of TET2 predisposes to other 
mutations.  Either way, the global hypermethylation phenotype in TET2 mutant cells 
must create the environment required for T-cell lymphomagenesis, and exactly how the 
other mutations fit in is still a puzzle that must be solved. 
The dominant negative G17V mutation in RHOA is particularly perplexing, though a 
variety of mutations in RHOA are known to occur in other cancers.  For essentially all 
cell lineages including most hematopoietic cells, RHOA acts to polymerize actin and 
controls contraction on the trailing or lagging edge during cellular migration.  RHOA was 
found to be a transforming factor in fibroblast culture,194 and its activity is very important 
in metastasis of many solid tumors;195,196 RHOA is frequently highly expressed in 
metastatic cancers.  Several other mutant forms of RHOA have recently been identified 
in diffuse gastric carcinomas.197  A plethora of RHOA mutations were also found in 
ATLL, some of which are activating and some inactivating.180  Notably, the most 
common mutants in the gastric cancers – Y42C, R5Q/W, and G17E –  are also expected 
to decrease GTP binding, though this has not been shown for R5 mutants.  Pediatric 
Burkitt lymphomas also have relatively frequent R5Q/W mutations in RHOA.180  
Together, this suggests a common mechanism of RHOA GTP-binding inactivation that 
promotes cancer development, though what exactly this is remains mysterious, 
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particularly because no G17V mutations occurred in gastric disease or Burkitt 
lymphoma, and because RHOA-activating mutations can also occur in the same 
diseases.  It would also be expected that if RHOA loss-of-function was oncogenic, then 
there would be examples of indels and nonsense mutations, and/or many more locations 
of mutation which would decrease RHOA activity.  The fact that there are specific 
mutational hotspots suggests a mechanism beyond simple loss, and/or only a few 
mutations are not maladaptive. 
Even the function of RHOA in lymphocytes has evidence somewhat difficult to 
reconcile.  Early work on thymocyte development (the process summarized under “From 
stem cell to mature αβ T-cell”) shows that RHOA activity is necessary for T-cells to 
mature, presumably because of 1) the intrathymic migration necessary for training, and 
2) the importance of actin in stabilizing the immunologic synapse.  Further, intercellular 
adhesion, which is initiated by transmembrane protein interactions but maintained by 
actin polymerization to keep adhesion proteins stable in the cell membrane, also 
requires RHOA function as specifically tested in Jurkat cells.198  Thus, a loss of GTPase 
function would be expected to reduce actin polymerization, and this is indeed shown for 
the G17V mutant.  Nevertheless, the total loss of functional RHOA in T-cells by 
transgenic expression of C3 exotoxin generates a T-acute lymphoblastic leukemia-like 
disease with thymic enlargement in mice.199 
One possible explanation for this strange behavior of RHOA G17V may relate to its 
affinities for other proteins in the so-called GTPase cycle.200  In order for GTPases like 
RHOA to function, they must be loaded with GTP.  Inactive GTPases are stably bound to 
GDP, and in the case of the Rho family, most are complexed in the cytosol with any of a 
class of guanine dissociation inhibitors, or GDIs; the prototypical GDI for RHOA is 
RhoGDI.  The GDI-bound fraction is in equilibrium with a small portion of membrane-
bound, inactive protein that can potentially be activated by guanine exchange factors 
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(GEFs, of which VAV1 is one) which catalyze the exchange of GDP for GTP.  The 
GTPase is now active.  For the GTPase to become inactive, the GTP must be 
hydrolyzed; this is by the action of GTPase accelerating proteins (GAPs), prototypically 
RhoGAP for RHOA, which increases the intrinsic activity of the GTPase, hydrolyzing the 
terminal phosphate bond of the GTP to generate GDP.  At this point, the GDP-bound 
GTPase can then re-complex with a GDI or be reactivated through the action of a GEF. 
Not only is RHOA G17V unable to bind GTP and be active, it is unable to bind 
guanine nucleotide at all.  Thus, it is hypothesized that the mutant RHOA may be 
“locked” in a conformation where it binds a GEF, but the GEF cannot dissociate because 
it cannot load GTP. If this were the case, there may be a preferential sequestration of 
some GEF or GEFs, allowing other GEFs or GAPs or GDIs to exert their pleiotropic 
effects on any number of cytosolic proteins.  Our laboratory is actively working on 
discovering what the important interactions for RHOA G17V might be.  One particularly 
interesting hypothesis (proposed by Timothy McKeithan) would be mostly lymphocyte-
specific: because VAV1 is among the most important GEFs for RHOA in T-cells, 
perhaps membrane-bound RHOA G17V sequesters VAV1 close to the plasma 
membrane, preventing dissociation.  VAV1 has many domains which can interact with 
many other proteins (see Figures 4 and 8) independent of its GEF function.  Thus, if 
VAV1 is constitutively membrane-bound, it may be able to activate other early 




Future directions: towards a model of PTCL, NOS and AITL 
 
Research in PTCL, NOS and AITL pathogenesis is hindered for several reasons as 
mentioned above.  Perhaps the most frustrating is a lack of PTCL models.  Other T-cell-
derived cancers such as T-cell leukemias and cutaneous T-cell lymphomas have several 
cancerous cell lines available publically from repositories such as the American Type 
Culture Collection (ATCC).  The former includes the cellular model used for the majority 
of this study, Jurkat; besides the fact that is a leukemic line, it also is not the best 
representation for normal T-cells because it is missing the tumor suppressor PTEN, 
which exerts a variety of its own effects on cell cycle, activation, and migration; thus, it 
likely dos not faithfully represent the human mature T-cell. 
AITL and PTCL, NOS, however, have never been successfully grown in vitro.  This is 
partially due to the relative patient infrequency, such that there has been less available 
to attempt to grow, as well as the paucity of historical and even current data concerning 
primary tumor drivers.  But the major reason is that both of these entities are strongly 
influenced by the micro-environment in which they develop.   As discussed in “COO: 
AITL,” the cells from which AITL are derived, TFH cells, are able to mature and stay alive 
as a differentiated TFH cell only in the presence of a germinal center, e.g. activated B-
cells and FDCs.  In vitro differentiation of TFH cells, or at least TFH-like cells, has been 
accomplished.  However, long- or even medium-term expansion of a non-cancerous TFH 
cell without B-cell and FDC interaction is as of yet impossible; our group has even tried 
to overexpress BCL6 in Jurkat cells, but to no avail (Jianbo Yu, unpublished data).  This 
is further underscored by the fact that AITL only extremely rarely undergoes a leukemic 
transition, in which the cells are able to stay alive while circulating in the blood without 
the constant support of the meshwork of the peripheral lymphoid tissues.  The only 
100 
 
foreseeable way truly generate a cell culture-based model of AITL is to develop a multi-
cell-type co-culture in which dendritic cells present an antigen to which both 
PRDM1loBCL6hiCXCR5hiCD4+ T-cells and mature B-cells are able to interact.  Only in 
this complex system can the appropriate degree of activation through the TCR, along 
with OX40 co-stimulation from B-cells and CD28 co-stimulation from both B-cells and 
dendritic cells, be maintained.  It is important to note that FDCs are important for T-cell 
training and do not normally take part in the GC reaction,93 but there still needs to a 
consistent, controlled, physiologic activation measure for the T-cells to become TFH. 
Practically, the one way to possibly accomplish the model outlined above would be to 
generate mice in some way.  We have generated mice with conditional loss of TET2 in 
T-cells to recapitulate what is found in human AITL and PTCL, NOS.  Mice expressing 
Cre recombinase under control of the Cd4 promoter (Jackson Laboratory, Tg(Cd4-
cre)1Cwi/BfluJ, stock 017336)  were crossed with mice which have the third exon of both 
their Tet2 alleles bounded by LoxP sites.133  Without Cre, cells have normal Tet2 
expression because the LoxP sites are spliced with the introns in which they sit.  
However, in the presence of Cre, the third exon of Tet2 is removed, such that all 
progeny of Cre-expressing cells, in this case CD4+ T-cells as well as perhaps some 
dendritic cells, will lose the third exon of Tet2 and not have a functional protein.  Some 
mice were also crossed with the OTII line, expressing a transgenic T-cell receptor which 
encodes an ovalbumin-specific TCR for MHC Class II, thereby allowing selective 
activation with a known antigen (Jackson Laboratory, B6.Cg-Tg(TcraTcrb)425Cbn/J, 
stock 004194). These mice are currently aging and will be assessed over their life for 
development of lymphoma.  Further, T-cells will be removed at various ages and 
assessed for functionality. 
T-cells from the murine lines above could potentially be used as donors for in vitro or 
in vivo work.  Another way to generate reactive T-cells could be through an acute 
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injection that would elicit an antibody reaction, such as sheep red blood cells; this will be 
less uniform, but would more appropriately generate a heterogeneous reaction more 
representative of the likely physiological reaction to antigenic challenge.  There are still 
other agents that could generate a known response, e.g. murine viruses, but for these it 
would be too easy to contaminate the mice intended to be uninfected.  This would be 
particularly problematic in a mouse facility at an academic institution that does not 
normally use biosafety level 2+ precautions or higher in routine handling and 
maintenance of mouse colonies. 
Even once these T-cells are ready to be used in modeling, the major issue remains 
recapitulation of normal nodal architecture.  For in vivo work, simple injection of 
potentially malignant T-cells should be enough to get them to home to peripheral 
lymphoid organs and divide as expected; only performing this experiment can decide.  
The in vitro modeling is even more complex.  Peripheral lymphoid organs are three-
dimensional structures, clearly, whereas tissue culture plates are two-dimensional.  
There do exist mesh inserts which adherent cells, FDCs in this particular model, could 
use as a scaffold and allowing multi-dimensional access for the potential interacting B 
and T cells, but it doesn’t let B- and T-cells move around each other with the dendritic 
meshwork in place.  Plus, gravity would pull non-adherent cells away from the insert 
towards the bottom of the well, and without moving lymph to keep cells in circulation, the 
lymphocytes would eventually not be able to interact with the FDCs anyway.  A round-
bottom plate would avoid the gravity issue but still not mimic the 3D structure of a lymph 
node.  It is truly a conundrum. 
Recent advances in bioengineering have generated organ-specific scaffolding which 
allows population by living, functional cells. In the functional cases (including heart,201 
liver,202 and pancreas,203 among others), the stated goal involves a single cell type 
(cardiomyocyte, hepatocyte, pancreatic β-cell, respectively) performing a cell-intrinsic 
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function in a position fixed in space.  For peripheral lymphoid organs, these strategies 
would not work so well, because these organs need specific inflow and outflow with 
many different cell types interacting, and most of these interactions are not fixed in 
space anyway.  Thus, a scaffold on which dendritic cells can grow would likely not be 
able to support a germinal center reaction or the migratory patterns of mature CD4+ T-
cells.  Perhaps in many years, there will exist an artificial lymph node or spleen which is 
able to function in all organ capacities, but that certainly is not just around the corner. 
One other possibility rests in the recent development of patient-derived xenograft 
(PDX) models, in which excisions of patient tumors are implanted in NOD/SCID/Il2rg-null 
(NSG) mice, and different potential chemotherapies are tried to assess the best 
response of the individual tumor.  These findings then inform the choice of therapy in the 
patient.  PDX models are fairly easy to generate for epithelial, solid tumors; in general, 
they can implant in almost any tissue.  For the PTCLs, especially the stromal-dependent 
tumors like the two diseases assessed here, this does not work as well, but has been 
previously met with moderate success.204  If PDXs can work consistently for biopsies of 
AITLs, then in addition to using the models to look at therapy, the tissue can propagate 
1) to give more cells for sequencing, and 2) allow long-term monitoring of cancer 
progression in a way that has certainly not been possible up to this point, thereby 
generating an extrinsic model which uses human cells. 
 
Conclusion: towards targeting co-stimulation for treatment of PTCLs 
 
Here we have studied the effects of mutations in proximal molecules of the T-cell so-
stimulatory pathway and found that they allow angioimmunoblastic T-cell lymphoma 
(AITL) and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) to increase 
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activation through the TCR, thereby increasing downstream signaling.  This signaling 
likely contributes to the survival of mutated cells, giving these cells the ability to 
contribute to lymphoma development and potentially resistance to therapy.  It is clear, 
from this and from others’ work, that the CD3/CD28 pathway is a central mechanism 
which prevents these cancerous cells from dying.  Therefore the co-stimulatory pathway 
is a rational target for these diseases. 
Altering CD28 biology, however, can have serious effects.  In a Phase I trial of a 
CD28 superagonist used to stimulate immune reaction, all six healthy individuals 
experienced cytokine storm and progressed to various degrees of organ failure, 
consistent with systemic inflammatory response syndrome (SIRS).205  Blocking of CD28 
activity through an inhibitory antibody has recently been successful in preventing acute 
kidney allograft rejection in non-human primates206 and is well-studied in rodents,207 
though titration for humans must be carefully done before clinical trial.  Other inhibitors of 
co-inhibitory CD28-family receptors already exist and are used in patients:208 anti-CTLA4 
(ipilimumab), anti-PD1 (nivolumab), and anti-PDL1 (atezolizumab) are used to increase 
immunologic response to solid tumors in humans.  More relevant to PTCLs, CTLA4-Ig 
(abatacept), which binds B7 ligand and prevents ligation with CD28, is already used 
successfully to treat many autoimmune diseases by preventing T-cell activation.  With 
proven tolerability, we hold that abatacept or similar classes of immune modulators 
should be considered for trial in PTCLs.  If a lymphoma is sequenced and has a 
TCR/CD28 activating mutation, then this drug may provide the key to prevent the signals 
which allow the cancer to persist. 
Someday soon, there will be a successful treatment for PTCLs.  It is only through 
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